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ABSTRACT
Medical marijuana is legal in twenty-nine of the United States and an additional
nineteen states have passed legislation for cannabidiol (CBD) treatment of drug-resistant
epilepsy, such as Dravet Syndrome (DS) which is diagnosed in children as young as two
months. While CBD has shown anecdotal and recently clinical trial efficacy in reducing
seizure frequency in DS patients, little is known about the potential adverse side-effects
on child physiology, brain development, adult disease, or subsequent generations.
Moreover, CBD is rarely administered without including low concentrations of Δ9tetrahydrocannabinol (THC). The goal of this project is to characterize the relative
morphological, behavioral, reproductive, and multigenerational toxicities following a
developmental F0 exposure to 0.024 - 5 mg/L (0.08 - 16 μM) THC or 0.006 - 1.2 mg/L
(0.02 - 4 μM) CBD. In this study, THC was used as a positive control due to its established
developmental toxicities. An additional goal of this project was to analytically confirm THC
and CBD concentrations during waterborne exposure as well as the bioconcentration in
zebrafish. Following a developmental exposure, CBD posed similar risk to development,
reproduction, and behavior as THC, but at much lower concentrations. Also, CBD
bioconcentrated in zebrafish more readily than THC. To our knowledge, this is the first
study to systematically compare the harmful effects on development and behavior of the
two most prevalent and widely used phytocannabinoids. While most patients with drugresistant forms of epilepsy and debilitating seizures choose cannabinoids in desperation,
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more research is necessary into their developmental toxicity to better understand both
their therapeutic and toxic mechanisms of action.
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CHAPTER 1 INTRODUCTION
1.1 Project Overview
Epilepsy afflicts an estimated 65 million people worldwide (Thurman et al., 2011)
and roughly 30% of patients have drug-resistant epilepsy (Romanelli et al., 2012; Williams
et al., 2014) wherein seizures are not adequately controlled with existing antiepileptic
drugs. Dravet syndrome (DS) is a prominent drug-resistant epilepsy beginning in infancy
with an incidence of roughly 1:16,000 to 1:21,000 (Krueger and Berg 2016). Among those
diagnosed with DS, ~75% carry a mutation in the voltage-gated sodium channel Nav1.1
(SCN1A) (Krueger and Berg, 2016). Efforts in validating a DS mouse model have proven
difficult due to unforeseen epileptic phenotypes (Grone and Baraban, 2015). Therefore,
zebrafish have become an excellent alternative for DS modeling as a result of inexpensive
breeding, easy introduction of genetic alterations, and proven developmental modeling
capabilities (Hortopan et al., 2010). Initial research utilizing scn1a deficient zebrafish has
identified new drug leads with potentially higher efficacies for DS (Baraban et al., 2014;
Zhang et al., 2015). Additionally, efforts in more generalized epileptic modeling using
zebrafish are also promising (Afrikanova et al., 2013; Buenafe et al., 2013; Rahn et al.,
2015; Rosa-Falero et al., 2015).
Due to relaxed prohibitions on marijuana use and therapeutic potential of cannabis
constituents in adolescent drug-resistant epilepsy, exposure of children to THC and CBD
is increasing. Yet the consequence of developmental exposure to cannabinoids on the
1

potential etiology of subsequent adult or multigenerational toxicity is currently unknown.
The goal of this project was to use the highly relevant zebrafish (Danio rerio) model to
study the potential toxicity of THC and CBD. Specifically, an adverse outcome pathway
(AOP) paradigm was used to eventually establish mechanistic relationships between
altered gene expression and phenotypic defects including developmental deformities,
behavioral alterations, and decreased reproductive success. THC was expected to have
adverse side-effects on brain development and reproduction, but little was initially known
about the toxicity of CBD. CBD is important due to popular CBD medications such as
CBD oil administration (e.g. Charlotte’s WebTM, http://www.theroc.us/) to patients,
especially young children, with epilepsy (Lindsey, 2016). While CBD has effective
antiepileptic properties (Devinsky et al., 2017), little is known about the potential for
persistent adverse outcomes. Mechanistic understanding underlying toxicity and
therapeutic efficacy of CBD is urgently needed (Porter and Jacobson, 2013; Szaflarski
and Martina Bebin, 2014).
When conducting literature searches related to CBD toxicity or mechanisms of
therapeutic action (Izzo et al., 2009; Pertwee, 2008) there are shockingly few published
studies. This is particularly perplexing given that CBD is being prescribed to a pediatric,
albeit desperate for treatment, population. There is a critical need for better understanding
of the molecular and physiological consequences of developmental exposure to THC and
CBD. AOPs, similar in concept to “mode of action”, provide a conceptual paradigm to link
a direct molecular initiating event between a xenobiotic and biomolecule and track effects
up biological levels of organization to the key risk assessment endpoint namely population
response (Ankley et al., 2010). AOPs significantly advance traditional toxicity testing
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paradigms and make use of new technological advances in transcriptomics, proteomics,
metabolomics, high-throughput assays, and bioinformatics (Villeneuve et al. 2014). Our
focus on brain neurodevelopment and behavior is particularly timely and will directly
complement new brain neuronal activity maps and behavior assays currently being
developed (Ahrens et al., 2013; Stewart et al., 2014).
Both the developmental origins of health and disease (DOHaD) and the potential
for subsequent multi- and/or transgenerational adverse outcomes are becoming more
appreciated in the scientific and health care communities (Heindel and Vandenberg,
2015; McMullen and Mostyn, 2009). Recently our lab (Corrales et al., 2014; Corrales et
al., 2014) and others (Baker et al., 2014) have proven that zebrafish are an advantageous
model for studying mechanisms of multi- and transgenerational toxicity. Capitalizing on
advantages of high fecundity, low culture costs, transparency and conserved (Howe et
al., 2013) developmental biology and genomics (Kettleborough et al., 2013), zebrafish is
an innovative approach for studying multigenerational toxicity. No existing mammalian
model affords all of these advantages. An additional distinctive advantage of using
zebrafish is the >1000 available transgenic lines that facilitate deformity scoring and
phenotypic anchoring (Weinstein, 2004). Namely, we will use transgenic fli [Tg(fli1:egfp)]
fish. Fli is a transgenic line wherein after 14 hours post-fertilization (hpf) the zebrafish
stably express enhanced green fluorescent protein in vascular endothelial cells (Lawson,
2002). Similar fish models have proven useful in high-throughput developmental
toxicology screening (Panzica-Kelly et al., 2010) of, for example, the ToxCast database
(Raftery et al., 2014). Importantly, developmental landmarks in zebrafish as they relate to
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AOP development have also been recently established (see Figure 1.1 in (Villeneuve et
al., 2014)).
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Figure 1.1 Adverse Outcome Pathway for THC and CBD Mediated Effects.
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CBD efficacy in epileptic animal models and children with drug-resistant epilepsy
is intriguing and will continue to gain attention as individual states in the United States
legalize the use of medical marijuana (Murphy and Ooyen, 2016). Unfortunately, while
CBD shows efficacy in reducing seizure frequency, little is known about the potential
adverse side-effects of CBD on child physiology, brain development, adulthood, or
offspring. Furthermore, the Schedule I designation of CBD limits its availability for
research and as a therapeutic (only approved for use in patients in 29 states) so new
plant-derived molecules or synthetic compounds may have enhanced efficacy against
epilepsy without scheduling liabilities. Our study design, using zebrafish, allows us to
determine the relative dose-dependent effects of THC and CBD in an easily screened
developing animal model. Our study provides significant new information relevant for
physicians and policy makers; specifically THC and CBD were assessed for causing:


developmental stage-specific differential gene expression in F0 and F1 larvae



adverse developmental morphologies (e.g. growth, edemas, brain development,
etc.)



reproductive success, and



behavioral phenotypes in exposed F0 larvae and unexposed F1 larvae.
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Figure 1.2 Adverse Outcome Pathway Schematic. Our approach began with a 96 hour
post fertilization (hpf) exposure to various concentrations of cannabinoids and structural
analogues. F0 larvae were analyzed for morphological, molecular, and behavioral
deformities. Exposed F0 fish were raised to maturity and undergo molecular, behavior,
and reproduction assessments. Finally, we spawned exposed F0 adults and conducted
similar analysis on F1 larvae.

7

1.2 History of Cannabis sativa
Marijuana (Cannabis sativa; Cannabis) has been used for several millennia for
medicinal purposes. The first recorded evidence of medical cannabis dates back nearly
five millennia to the Chinese emperor, Shen-Nung (Bostwick, 2012), and eventually
spread westward to India and Africa around 2000 BC. In North America, hemp, an
industrialized form of Cannabis sativa containing very low concentrations of THC, is
thought to have first arrived with Puritan colonizers in the early seventeenth century.
Toward the middle of the seventeenth century, hemp was being produced in large
quantities and used for its fibrous characteristics such as paper, cloth, and cordage for
marine vessels (Will, 2004). Throughout the eighteenth and nineteenth century, hemp
demand and production began to decrease as alternative forms of water transportation
were developed, such as steam boats (Will, 2004). Politics also played a role in hemp’s
demise via the 1937 Marijuana Tax Act which did not completely outlaw hemp production,
but placed a tax and authorization that the crop would no longer be used for illicit
purposes.
Medicinal cannabis was first introduced to the United States in 1830 by W.B.
O’Shaughnessy, a Scotland born pharmacist (Bostwick, 2012). O’Shaughnessy claimed
cannabis could be used therapeutically for indications such as nausea, pain, and even
seizures or convulsions. In the late 1800s through the early-1900s, cannabis was widely
used across the United States and found in numerous pharmaceuticals, that is, until the
1937 Marijuana Tax Act was enacted (McKenna, 2014). Much like the hemp industry,
medicinal use of cannabis was also limited and ultimately discontinued after the war on
drugs campaign by the Nixon administration, which lead to the Controlled Substances Act
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of 1970, part of the Comprehensive Drug Abuse Prevention and Control Act of 1970. The
Controlled Substances Act contained five classifications of potential of abuse. Cannabis
was classified a Schedule I drug, which is the most restrictive classification and proposes
no medical benefit.
Within the late 1990’s and early 21st century, medical cannabis has shown a strong
resurgence for therapeutic uses ranging from depression, schizophrenia, and chronic
pain to epilepsy and even cancer, due to complications with chemotherapy. Even though
medical cannabis has shown potential in many areas of therapeutic treatment, it is still
characterized as a Schedule I drug in the United States via the 1970 Controlled
Substance Act and is illegal under Federal Law. However, 29 states have passed medical
cannabis legislation within the United Sates and a number of additional states possess
laws specific for CBD drug trials and regulate the way in which patients obtain medical
cannabis (ProCon.org, 2017). Cannabis usage per state varies drastically, some states’
(RI, VT, AK, OR, WA, CO, MT) are estimated to have >10% cannabis use within the past
month (Palamar et al., 2014). Exposure to cannabinoids will likely increase due to an
increasing number of states relaxing cannabis regulatory policies and allowing medical
cannabis prescriptions (Consroe et al., 1982).
In 1999, the Institute of Medicine released a study suggesting cannabis may have
some medicinal benefit for applications such as loss of appetite, nausea and vomiting,
and severe pain (Bostwick, 2012). More recently, CBD has gained traction in the
treatment of pediatric drug-resistant epilepsy. In a study with 19 children with a range of
epileptic disorders (Dravet syndrome, Doose syndrome, Lennox-Gastaut syndrome, and
idiopathic epilepsy) treated with CBD-enriched cannabis (from 0.5-28.6 mg/kg/day CBD
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and 0-0.8 mg/kg/day THC), 84% (n = 16) of the children experienced reduced seizure
events and 11% had no seizure events (Porter and Jacobson, 2013). CBD showed an
improved therapeutic outcome in a wide variety of epilepsy animal models including transcorneal electroshock and PTZ-induced seizure models (Jones et al., 2010; Renard et al.,
2014). While CBD may be an effective treatment option for children with epilepsy, the
effects of CBD on child development and behavior and/or effects of childhood CBD
treatment in adulthood and on future offspring are currently unknown (Szaflarski and
Martina Bebin, 2014). In contrast, studies have shown a direct connection between
chronic cannabinoid receptor agonist exposure and lifelong cognitive dysfunction in
adolescence (Renard et al., 2014). Data suggests a reduction in memory, attention,
decision-making, IQ, and cognitive inhibition (Higuera-Matas et al., 2015; Jutras-Aswad
et al., 2009). Additionally, the effects of chronic cannabis abuse on the developing brain
and early cognition include the induction of tremors, increased startle response, and poor
habituation to stimuli in newborns and infants (Huizink and Mulder, 2006; Panula et al.,
2010).
In the end, despite these suggested therapeutic effects of CBD for seizure control
and the adverse neurobehavioral outcomes of THC exposure, the molecular
underpinnings of these effects are not fully known. Because of the relatively conserved
neuroanatomy, neurochemistry (Lam et al., 2006) including cannabinoid receptor 1
signaling (Migliarini and Carnevali, 2009; Rodriguez-Martin et al., 2007) and behavior
(Akhtar et al., 2013; Bruni et al., 2014) between zebrafish and mammals, the AOP linking
molecular to organismal responses is highly translatable to humans. Symptoms of THC
developmental toxicity include pericardial and yolk sac edemas, curved body axis and
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behavioral habituation at 120 hpf (Noyes et al., 2015) while acute adult exposure caused
hypolocomoter/anxiogenic-like responses (Grossman et al., 2010). Additionally, larval
zebrafish respond to convulsant drugs (e.g. pentylenetetrazol (PTZ) recapitulating
seizures similar to mammals.

1.3 Cannabinoid Signal Transduction
More recently, the scientific community has focused its efforts into the effects of
the endocannabinoid system (EDC) on neuronal activity, inflammation, energy
metabolism, regulation of the immune system, reward systems, and memory. The EDC
has been implicated in diseases such as, type II diabetes and liver disease. The primary
receptors involved in cannabinoid signal transduction are cannabinoid receptor I (CB1)
and II (CB2) that operate in a G-protein-coupled receptor (GPCR) manner. Distribution of
cannabinoid receptors differ receptor to receptor; CB1 is currently thought to primarily
concentrate in the central and peripheral nervous systems while CB2 is primarily
expressed in the immune system. Although, much debate encompasses the individual
actions of CB1 and CB2, CB1 receptors have been connected to cardiovascular activity,
regulation of the gastrointestinal tract, stress, and olfaction. CB2 actions are less known,
but include immune regulation and neurodegeneration (Szaflarski and Martina Bebin,
2014).
The EDC is highly conserved in vertebrates encompassing a wide variety of signal
processes

from

neuronal

development

and

signaling

to

immune

response

(Basavarajappa et al., 2009; B Migliarini and Carnevali, 2009; Psychoyos et al., 2012;
Watson et al., 2008). These processes are carried out via two GPCRs, CB1 receptor
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(CNR1, human gene, CB1, human protein; Cnr1, rodent gene, CNR1, rodent protein;
cnr1, zebrafish gene, Cnr1, zebrafish protein) and CB2 receptor (CNR2, human gene,
CB2, human protein; Cnr2, rodent gene, CNR2, rodent protein; cnr2, zebrafish gene,
Cnr2, zebrafish protein) (Krug and Clark, 2015).
Due to recent advancements in EDC mapping and cannabinoid receptor tissue
localization, focus on cannabis efficacy in various other disorders, such as epilepsy, has
increased. Regarding cannabis therapeutic usage, two endocannabinoid extracts are of
current interest; the primary psychoactive compound THC and a non-psychoactive
compound, CBD. While the mechanisms of action are not entirely known, THC and CBD,
in concert with the EDC, have an important mechanistic role in the propagation and
maintenance of seizures in animal models.
THC has high affinity for the CB1 receptor, while CBD is thought to have a very
low CB1 affinity, but has shown the ability to displace CB1 antagonists (Szaflarski &
Martina Bebin., 2014; Wallace et al., 2002; Wallace et al., 2003 & Jones et al., 2010).
Although cannabinoid efficacy has been shown in maximal electroshock animal models
versus controls, a wide range of blind studies in human epileptic patients have proven
inconclusive in THC and CBD treatment (Szaflarski & Martina Bebin, 2014). In addition
to CBD having an increased efficacy in maximal electroshock animal models, CBD has
shown an improved therapeutic outcome in a wide variety of epilepsy animal models;
including transcorneal electroshock models and pentylenetretrazole (Consroe, et al.,
1982 & Jones et al., 2010). In epileptic animal models, CBD is more effective active
cannabinoid compound. In the United Kingdom, THC and CBD are being used in Sativex,
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a THC:CBD (1:1) pharmaceutical used to treat severe pain caused by multiple sclerosis
and cancer (Jones et al., 2010).
Activation of GPCRs occurs when an endogenous or exogenous ligand interacts
with the binding pocket resulting in a guanine exchange between guanosine diphosphate
(GDP)/guanosine triphosphate (GTP) and interplay with α-, β-, and γ-subunits
(Basavarajappa et al., 2009). Guanine exchange factors (GEF) catalyze the transfer of
guanine to guanosine triphosphate which is coupled with the α-subunit. Once GDP is
replaced with GTP, the α-subunit detaches from the βγ-subunits and diffuses across the
membrane activating an effector turning on the GPCR (Basavarajappa et al., 2009;
Norman and Litwack, 1997). Signaling can be further turned “off” by hydrolysis of GTP
via GTPase resulting in the re-association of GDP and α-subunit to the βγ-subunit
complex (Wettschureck and Offermanns, 2005). Cannabinoid receptors belong to the
Gi/Go family of GCPRs which refers to specific type of α-subunit. Gi/Go subfamily of
GCPRs have an inhibitory effect on adenylyl cyclase decreasing cyclic adenosine
monophosphate (cAMP) while also positively affecting potassium channels activity
(Birnbaumer, 2007).
Endogenous ligands for cannabinoid receptors (endocannabinoids) have been
well established within the past few decades and possess a broad range of action in a
large variety of pathways. Notably, anandamide (AEA), was the first endocannabinoid
discovered in 1992 by (Devane et al., 1992) from porcine brain fractions. AEA is regarded
as a partial agonist of CB1 receptor and an inactive CB2 agonist (Szabo and Hoffman,
2012). A second endocannabinoid, 2-arachidonylglycerol (2-AG), was elucidated from
canine gut (Mechoulam et al., 1995; Sugiura et al., 1995). 2-AG is considered a full

13

agonist at both CB1 and CB2 (Szabo and Hoffman, 2012). A few other endocannabinoids
have been identified, 2-AG ether, virodhamine, and N-arachidonyl-dopamine, however
little is known with regard to their physiological roles (Basavarajappa et al., 2009).
Chemical structures of the listed endocannabinoids and phytocannabinoids are
represented in Figure 1.3-1.4.
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Figure 1.3 Endogenous cannabinoid receptor ligand structures. (PubChem, 2017).

Figure 1.4 Most prevalent phytocannabinoid structures. (PubChem, 2017).
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CB1 belongs to the rhodopsin subfamily A13 of GPCRs and is primarily expressed
in regions of the brain imperative for memory, cognitive development, and learning
(Demuth and Molleman, 2006). The physiological role of CB1 was first characterized by
(Howlett and Fleming, 1985) using the phytocannabinoid, THC. Following THC exposure
to neuroblastoma cells, adenylyl cyclase was inhibited which eventually lead to a
reduction of cAMP. Further analysis using a CB1 antagonist, AM 281, showed a reversal
of this inhibitory effect leading to recovered cAMP production. cAMP is an imperative
second messenger in cells with three distinct targets for signal transduction: cAMP protein
kinase (PKA), cAMP response element binding protein (CREB), and cAMP guanine
exchange factors (EPACs) (Goodman and Gilman, 2011). PKA is conformationally
activated by increased intracellular concentrations of cAMP leading to phosphorylation of
threonine and serine residues on target proteins which further enhance downstream
signaling. The target proteins of PKA can range from metabolic enzymes to highly
regulated proteins involved in kinase activity. CREB activation can lead to important gene
expression-related processes such as, increased transcription of the aryl hydrocarbon
receptor (AhR), glucocorticoid receptor, insulin, and many others. EPACs are involved in
many cell functions including activation of the Ras family of GTPases and can act
independent or in concert with PKA (Goodman and Gilman, 2011).
In order to better elucidate the type of GCPR for which cannabinoid receptors
represent, pertussis toxin (PTX), a Gi/o specific uncoupler of the α-subunit (Mangmool and
Kurose, 2011), was used to block the inhibitory action of THC. This competitive inhibition
confirmed that CB1 is a Gi/o specific GCPR (Howlett and Fleming, 1985). The complexity
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of cannabinoid signaling can be further evaluated through the nine isozymes of adenylyl
cyclase categorized in six classes (Demuth and Molleman, 2006):


Class I: AC-1. Found in the brain and inhibited by Gβγ/Giα and activated by
Ca2+/calmodulin.



Class II: AC-II, AC-IV, and AC-VII. Found in the brain and additional unknown
locations. With Gαs, these isoforms are turned on by Gβγ.



Class III: AC-III. With Gαs, AC-III is activated by Ca2+/calmodulin.



Class IV: AC-V and AC-VI. Found in heart and brain, Giα inhibition with Ca2+.



Class V: AC-VIII. Found in brain with Ca2+/calmodulin activation.



Class VI: AC-IX. Found in brain and skeletal muscle and regulated by G αs.
Tissue specificity along with complex regulatory mechanisms of adenylyl cyclase

increases the likelihood of phytocannabinoid toxicities responding in contrasting ways
depending on the cannabinoid receptor concentration in target and adjacent tissues.
Along with adenylyl cyclase activation via CB1 receptors, mitogen-activated protein
(MAP) kinases have also been correlated with cannabinoid signaling. Synthetic
cannabinoid CP 55,940 as well as HU-210, a synthetic cannabinoid found in the popular
recreational drug Spice, activate MAP kinase activity in Chinese hamster ovary (CHO)
cells; however, off-target effects of these cannabinoids are still under investigation
(Bouaboula et al., 1995; Galve-Roperh et al., 2002). Additionally, this action was reversed
following PTX exposure which implies Gi/o (i.e., CB1/CB2) involvement. In vivo studies in
rodents after THC exposure have also supported MAP kinase activation claims via CB1
(Valjent et al., 2001). MAP kinase is a very important CB1 signaling target especially in
this present study due to the ramifications of c-fos and brain derived neurotrophic factor
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(BDNF) (Demuth and Molleman, 2006). Following THC exposure in mice, (Derkinderen
et al., 2003) both c-fos and BDNF had increased protein concentration and were
subsequently reduced after MAP kinase inhibition.
Possibly the most elusive signaling pathways of CB1 and possibly cannabinoids
independent of receptors is the regulation of ion channels. Ion channel regulation through
CB1 or cannabinoids directly is thought to be the primary mechanism by which
neurotransmitter release an affect following exposure. Cannabinoids (CP 55,940, AEA,
and WIN 55,212-2) were first described (Felder et al., 1993; Mackie and Hille, 1992) to
negatively modulate N-type voltage-operated calcium channels (VOCCs) reducing Ca2+
influx through CB1 mediated processes. Gi/o type GPCRs were confirmed to mediate this
interaction through PTX reversal (Mackie et al., 1993). Cannabinoids also act
independently in inhibiting Ca2+. SR 141716A, a potent antagonist of cannabinoid
receptors in the brain is not effective in blocking the inhibitory role of WIN 55,212-3 on
Ca2+ signaling (Shen and Thayer, 1998). One interesting component of ion channel
regulation via cannabinoids is that this signaling is CB1-specific with CB2 lacking this
characteristic.
CB2 also acts in an adenylyl cyclase and MAP kinase dependent manner via Gi/o.
As mention previously, CB2 receptors are currently thought to not possess ion channel
activation (Felder et al., 1995). Also, verified through the lack cAMP accumulation in CHO
cells following HU210 treatment, Gs coupling is not a characteristic of CB2 receptors
(Glass and Felder, 1997). In order to further elucidate CB2’s cannabinoid activity, MAP
kinase (p42/p44) activation in CHO cells expressing high concentrations of CB2 can be
reversed using PTX (Bouaboula et al., 1996). CB2 has also been implicated in the signal
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transduction of THC which activates PI3K/PKB and Raf-1 translocation in prostate cells,
PC-3. Treatment of PC-3 with CB2 receptor antagonist, SR 144528, blocks this action
(Sánchez et al., 2003). Additionally, the immune system characteristics of CB2 have been
implied in studies showing IL-2 inhibition, presumably downstream of MAP kinase
inhibition, in mouse spleen tissue following WIN 55,212-2 exposure (Kaplan and
Kaminski, 2003). However, it should be noted that WIN 55,212-2 has low affinity (3.3 ±
0.4 nM) to CB2 compared to other agonist such as AEA (1940 ± 240 nM), and WIN
55,212-2 has substantially greater affinity for CB1 (62.3 ± 31 nM) (Felder et al., 1995).

1.3.2 Zebrafish Endocannabinoid System
One of the benefits of using zebrafish as a cannabinoid toxicity model is the
conserved nature of their EDC to mammals. The EDC system is not well conserved in
invertebrate model organisms such as, Drosophila or C. elegans (Krug and Clark, 2015).
Zebrafish express both cannabinoid receptors primarily in the brain (hind-, mid-, and
forebrain), but also in peripheral tissues such as ovary, intestine, spleen, and heart (Lam
et al., 2006; Migliarini and Carnevali, 2009; Rodriguez-Martin et al., 2007). CB1 mRNA
(cnr1) has been observed as early as the three somite stage and increases through the
25 somite stage, while CB1 protein (63 kDa) has been measured via whole-mount in situ
hybridization at 48 hpf through 15 days post fertilization (Migliarini and Carnevali, 2009).
CB2 mRNA has been less studied; however, Rodriguez-Martin et al (2007) observed CB2
expression in brain regions in adult zebrafish with RT-qPCR only. In situ techniques to
identify CB2 in the brain were inconclusive (Rodriguez-Martin et al., 2007).
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Regarding endocannabinoid signaling, diacylglycerol lipase (DAGL) and fatty acid
amide hydrolase (FAAH) have been studied minimally in zebrafish. DAGL, the primary
catalytic enzyme for the synthesis of 2-AG, expression has been observed in the
hypothalamus, telencephalon, and hindbrain regions of developing zebrafish at
comparable concentrations to cnr1 (Watson et al., 2008). One difference between DAGL
and cnr1 expression is the presence of DAGL in the posterior and anterior hindbrain
(Watson et al., 2008). Zebrafish retina is associated with FAAH expression; however,
studies are lacking in this area of zebrafish biology (Yazulla and Studholme, 2001).

1.4 Cannabinoid Toxicity
Toxicities resulting from THC exposure are well documented and range from
cognitive decline to reproductive impairments; however, adverse effects following CBD
exposure have been less explored. Elucidating cannabinoid pharmaceutical prowess has
been researched since the early 1940’s. In humans, THC is an established reproductive
toxicant (Lewis et al., 2012). Cannabis use in men causes a reduction in
endocannabinoids (e.g. AEA and 2-arachidonoylglyceral) responsible for THC signal
transduction in seminal plasma. Moreover, infertility is a direct consequence of THC
exposure via the transient receptor potential cation channels (TRPV1) receptor (Lewis et
al., 2012). Studies also suggest low birth weights (< 2,500 g) and preterm deliveries in
children after regular maternal cannabis use (Gunn et al., 2016). One of the major issues
related to the previously mentioned research is how cannabis is consumed. Most current
literature studying exposure effects involve smoking cannabis; therefore, it is impossible
to control for the coupled onslaught of products from combustion such as polycyclic
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aromatic hydrocarbons (PAHs). Therefore, the studies discussed herein will be limited to
those conducted in controlled settings following pure compound exposure in a host of
relevant model organisms. In addition, THC is the most abundant compound found in
cannabis, hence data derived directly from solely CBD exposure is lacking in the
toxicology community. Select phytocannabinoid toxicity publications are listed in Table
1.1.

1.4.1 Reproduction and Teratogenicity
One of the earliest publications studying the potential teratogenicity of
cannabinoids was in 1967 by Persaud and Ellington. Mouse embryos were I.P. exposed
to 16 mg/kg cannabis resin at 1 to 6 days of gestation and screened for developmental
abnormalities and pregnancy success (Persaud and Ellington, 1967). Embryos exposed
at gestational day 6 experienced impeded growth, while embryos exposed from day 1
through 6 of gestation were more likely to undergo fetal resorption. However, no
detectable developmental malformations were observed in exposed embryos (Persaud
and Ellington, 1967). The same group later studied the potential teratogenic effects of 4.2
mg/kg cannabis resin on pregnant rats again on 1 to 6 days of gestation. Fetal resorption
as well as malformed fetuses were significantly increased in exposed mothers compared
to control (Persaud and Ellington, 1968). It should be noted that the previous studies were
both conducted with crude cannabis resin which includes a number of phytocannabinoids
including undisclosed compounds. Early studies have also been conducted in rabbits for
potential teratogenicity following cannabis exposure. Resorption percentages in addition
to runt-like phenotypes were greatly increased after mothers were exposed to amounts
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of cannabis extract > 250 mg/kg (Geber and Schramm, 1969). Developmental
malformations were also observed in embryos whose moms were exposed to
concentrations > 250 mg/kg (Geber and Schramm, 1969). More recent literature has also
focused on the potential developmental and embryonic effects of THC, synthetic THC
(sTHC), and endogenous CB ligands. Win 55212-2, THC, CP 55,940, and AEA can inhibit
mouse blastocyst formation, significantly arresting development between the four to eight
cell stage (Paria et al., 1995). Interestingly, the same study showed CBD and 2-AG to be
ineffective against developmental inhibition (Paria et al., 1995).
The effects of endogenous cannabinoids adversely affecting development and
fertility is well known (Lockwood, 2000; Maccarrone and Finazzi-Agro, 2004). For
example, AEA, through MAPK mediated pathways reduce blastocyst viability; therefore,
implying that AEA degradation is crucial for implantation and early development (Wang
et al., 2003). Consequently, FAAH, the enzyme responsible for AEA’s degradation, is also
correlated with the early loss of pregnancy (Lockwood, 2000). Specifically, FAAH is
needed in order to maintain pregnancy, so patients lacking FAAH are more likely to
miscarry than patients expressing FAAH at concentrations above a threshold
(Maccarrone and Finazzi-Agro, 2004). Fluctuating FAAH and AEA levels during early
stages of pregnancy through fetal development have been observed in both humans and
mice (Paria and Dey, 2000).
Following the initial teratogenic screens in mammals, some follow-up studies were
conducted in zebrafish measuring embryo toxicity and development. Zebrafish embryos
were exposed to sTHC at concentrations ranging from 1 to 10 mg/L and subsequently
screened for developmental abnormalities and involuntary tail movement. Embryos
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exposed to concentrations > 5 mg/L sTHC experienced fewer spontaneous tail twitches
compared to control, suggesting potential toxicity relating to the CNS (Thomas, 1975).
Thomas also observed a significant increase in mortality at 5 and 10 mg/ml sTHC.
(Thomas, 1975). While Thomas was not the first to elucidate zebrafish developmental
toxicities (Battle and Hisaoka, 1952; Hisaoka, 1958), his work with zebrafish and THC
helps us understand historical data and how gaps still exist in cannabis’ toxicity profile.
The developmental and teratogenic properties of phytocannabinoids have also
been characterized in zebrafish (Akhtar et al., 2013; Stewart and Kalueff, 2014; Thomas,
1975; Wright et al., 1976). Initial studies have focused primarily on embryo survival, while
more recent research has eluded to behavioral phenotypes and neurotoxicity (Akhtar et
al., 2013; Nazario et al., 2015a; Stewart and Kalueff, 2014). In zebrafish, THC LC50
concentrations were first established by (Akhtar et al., 2013) at roughly 3.37 mg/L, which
is consistent with our findings. Akhtar’s group also observed curved axis, yolk sac and
pericardial edemas (> 0.6 mg/L) as well additional dysmorphologies that were not
reported such as craniofacial deformities following THC exposure. Our findings confirm
the dysmorphologies seen by Akhtar.

1.4.2 Cognitive Impairment and Behavior
Cannabinoids have the ability to not only affect neurodevelopment at the molecular
and structural level, but chronic use can also drastically impair learning, memory, and
cognitive ability (Akhtar et al., 2013; Fishbein et al., 2012; Hampson et al., 1989; Horrall
et al., 1976; Long et al., 2010; Morgan et al., 1988; Nazario et al., 2015a; Renard et al.,
2014; Ruhl et al., 2014; Stewart and Kalueff, 2014). Consideration of exposure windows
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is imperative for the variety of adverse outcomes. For example, chronic use in adolescent
aged children is correlated with impulsive behavior, impaired executive function and
decision making, a reduction in comprehensive IQ, and can negatively affect attention
and memory (Becker et al., 2010a, 2010b; Crane et al., 2013; Dougherty et al., 2014;
Ehrenreich et al., 1999; Fontes et al., 2011; Medina et al., 2010; Meier et al., 2012;
Schweinsburg et al., 2008; Solowij et al., 2012).
Memory is a basic measurement of neurocognitive function and predictor of
fundamental mental fitness. Females seem to be more susceptible to the adverse effects
of chronic cannabis use, especially as it relates to memory tasks (Crane et al., 2013). It
has even been postulated that cannabis may interrupt hippocampal dendrite maturation
in an estrogen-dependent manner (Gillies and McArthur, 2010). However, both males and
females perform poorly in memory recall assessments and decision making following
chronic cannabis use (Crane et al., 2013).
Behavioral observations were conducted in zebrafish following THC exposure
during early stages of development (Akhtar et al., 2013) and later in adulthood
(Champagne et al., 2010; Nazario et al., 2015a; Ruhl et al., 2014; Stewart and Kalueff,
2014). One of the primary mechanisms for characterizing neurodevelopmental toxicities
in zebrafish is via a light:dark cycling assessment (Kirla et al., 2016). Both acute (1, 4, 12
hour) and chronic (96 hour) exposure reveal THC and sTHC (WIN 55,212-2 and CP
55,940) significantly reduced locomotor behavior in zebrafish (Akhtar et al., 2013). In adult
zebrafish, researchers have conducted more stringent behavioral tests including, learning
(Braida et al., 2014; Ruhl et al., 2014; Saili et al., 2012), anxiety and stress (Jesuthasan,
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2012; Nazario et al., 2015a, 2015b; Saili et al., 2012; Stewart and Kalueff, 2014), and
social attributes (Grossman et al., 2010; Kalueff et al., 2014).
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Table 1.1 Select Phytocannabinoid Toxicity Publications
Species

Phytocannabinoid

Experimental Endpoints

Zebrafish

THC

Lethality; Development;
Behavior; Reproduction

Rat

Mouse

References
(Akhtar et al., 2013;
Thomas, 1975; Wright et
al., 1976)

Cognitive Function

(Ruhl et al., 2014)

CBD

Metabolism

(Silvestri et al., 2015)

THC

Lethality; Physiology

(Phillips et al., 1971)

Metabolism

(Narimatsu et al., 1990)

Reproduction

(Wright et al., 1976)

CBD

Food Intake

(Koch, 2001)

THC

Reproduction; Development

(Harbison et al., 1977)

Lethality; Physiology

(Phillips et al., 1971)

Metabolism

(Pelkonen et al., 2008)

Physiology

(Dirikoc et al., 2007)

CBD

Pig

THC

Metabolism

(Brunet et al., 2006)

Monkey

THC

Physiology; Metabolism

(Slikker Jr et al., 1991)

CBD

Convulsions; Organ Weight

(Rosenkrantz et al., 1981)

THC

General Toxicity

(Brill et al., 1970)

Neurology

(Fusar-Poli et al., 2009)

Fertility

(Lewis et al., 2012)

Physiology; Neurology

(Cunha et al., 1980;
Fusar-Poli et al., 2009)

Human

CBD
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1.5 RT-qPCR and Genes of Interest
In this study, embryos/larvae were collected from across the concentrationresponse curve and treatments after 14, 24, 48, 72 and 96 hpf for RT-qPCR analyses of
the selected genes. Each time point represents a key developmental stage in
morphogenesis and neurogenesis signaling that may be disrupted by cannabinoid
exposure (Grossman et al., 2010). We hypothesized that altered expression of bdnf (Collo
et al., 2014), c-fos (Stranahan et al., 2013), and reln (Folsom and Fatemi, 2013; L. Wang
et al., 2006) were indicative of neurotoxicity. Key morphology and reproductive biomarker
genes include sox2, sox3, and sox9a (Bal-Price et al., 2015; Fang et al., 2010), vasa
(Williams et al., 2014) and dazl (Li et al., 2016). Cannabinoid receptors (cnr1 and cnr2)
(Krug and Clark, 2015)) were measured to determine if exposure altered their basal
expression. Primer sequences and primer optimization information can be found in Table
2.1.

1.5.1 c-fos
c-fos is primarily expressed in the zebrafish brain (Baraban et al., 2005) and wellestablished biomarker for characterizing neuronal activity, which is particularly critical
when studying the therapeutic potential of novel anti-seizure drugs. c-fos is also a
potential mitogenic marker; however, research is inconclusive in this area. One of the
original studies to research c-fos in depth was by Morgan et al., 1987; wherein they
mapped the patterns of c-fos during seizure events, and used known anti-seizure
medication to elucidate c-fos expression profiles. The results indicated that c-fos mRNA
expression was directly correlated to PTZ seizure stimulation from 15 minutes to as late
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as 180 minutes and also in a concentration-dependent manner from 0 mg/kg to 50 mg/kg
(Morgan et al., 1987). In addition, studies were conducted to assess the effect of known
anti-seizure medications such as diazepam on the expression of c-fos. Following PTZ
treatment, diazepam effectively reduced c-fos mRNA expression while a DMSO/PTZ
exposure proved to be ineffective (Morgan et al., 1987). Since this report, the use of cfos in zebrafish (Afrikanova et al., 2013; Baraban et al., 2005; Ellis et al., 2012; Rahn et
al., 2015; Ruhl et al., 2014) and mice (Buenafe et al., 2013; Morgan et al., 1987; Sonego
et al., 2016), primarily as a marker of seizure-like molecular attributes was confirmed.

1.5.2 bdnf
Neurodevelopment through early developmental stages, and cognitive decline
later in life have both been correlated with bdnf expression and signal transduction
(Angelucci et al., 2010; De Felice et al., 2014). This especially holds true for neuronal
degeneration and plasticity, which potentially affect cognitive functions such as, learning
and memory, social interaction, and mental health (Angelucci et al., 2010; Bekinschtein
et al., 2008; Budni et al., 2015; Cunha et al., 2009). bdnf is expressed throughout the
mammalian, human, and zebrafish CNS with prominent presence in brain regions (Budni
et al., 2015; Cacialli et al., 2016; De Felice et al., 2014; Maisonpierre et al., 1990).
Analysis of bdnf expression in both larval (whole body homogenate) and adult zebrafish
(brain tissue homogenate) will help identify potential adverse effects on both the
developing, adolescent, and aging brain, which could be directly correlated with
behavioral phenotypes such as, developmental neurotoxicity (larval light:dark analysis)
(Kirla et al., 2016), learning and memory (T-maze) (Braida et al., 2014), social interaction
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(shoaling behavior) (Grossman et al., 2010), and mental health i.e., anxiety (novel tank
test (Kyzar et al., 2013) and open field (Grossman et al., 2010)).

1.5.3 dazl and vasa
Maintaining germline stability across generations is imperative for reproductive
fitness. Our molecular marker for tracking the status of germline function was deleted-inazoospermia-like (dazl) gene which is among the larger Daz family of genes (Li et al.,
2016). dazl, along with other genes and factors, is imperative for primordial germ cell
maturation, which is critical for the development of both spermatozoa and oocytes. These
genes are maternally inherited and concentrate early in development in the upper yolk
sac of zebrafish (Hashimoto et al., 2004). Measuring the expression of dazl from early
development (14 hpf) through adulthood in the F0 and F1 generation will allow us to
directly track the maintenance of the germline in a dazl-dependent manner. Contrary to
p-element induced wimpy testis (piwi) RNA which is essential for male germ cell
development (Tan et al., 2002), vasa is critical for germ call development in females
(Anderson et al., 2007). Studies have observed DAZL and VASA proteins co-localized
and working in concert with one another in the maturation of germ cells regardless of sex
(Anderson et al., 2007).

1.5.4 sox2, sox3, reln
Similar to bdnf, sex determining region Y-box (sox2) is a transcription factor
involved in many pathways connected with neuronal development as well as cognitive
impairment such as learning and motor dysfunction to seizures (Kelberman et al., 2006;
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Sisodiya et al., 2006). Complete loss of sox2 expression was directly associated with
multiple eye development disorders like microphthalmia and anophthalmia (Hever et al.,
2006). Another more general transcription factor, sox3¸is also involved with neuronal
development (Dee et al., 2008), and is critical for the transition of both neuronal and nonneuronal fate stem cells (Dee et al., 2007). Studies in zebrafish have shown exogenously
expressed sox3 to form tissue with neuronal characteristics (Dee et al., 2007). Lastly, reln
has been associated with various cognitive disorders such as autism (Fatemi et al., 2005)
and schizophrenia (Fatemi, 2001). Mice carrying reln mutations experience numerous
neurodevelopmental phenotypes from incorrectly placed neurons to cerebellar
hypoplasia (Goffinet, 1984).

1.5.5 krit1, sox9
Genes that are critical for specific developmental endpoints include cerebral
cavernous malformations gene or (krit1) which is important for the development of smooth
muscle cells and organization of cardiac tissue. krit1’s expression was expected to
correlate with malformed cardiac chambers (Chen et al., 1996; Wüstehube et al., 2010).
Specifically, due to the increased incidence of pericardial edemas observed in zebrafish
exposed to THC and CBD, and what seemed like a disorganization or lack of heart
morphology, krit1 was screened.. sox9 is another transcription factor that is important for
the formation of bone and cartilage (Yan et al., 2005). Zebrafish mutants lacking sox9,
reveal a specific phenotype of an inwardly curved axis. This inwardly curved axis is not
typically observed by our lab during morphology screening; however, these mutants are
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also characterized by a significant jaw dysmorphology (lack of a jaw), which is commonly
observed (Yan et al., 2005).

1.5.6 18s
Ribosomal RNA (18s) is a well-established, stable reference gene used to carry
out RT-qPCR analysis (Bas et al., 2004; Filby and Tyler, 2007; McCurley and Callard,
2008; Tang et al., 2007; Y. Wang et al., 2006).
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1.6 Aims and Hypothesis Statement
The goal of this project was to study the reproductive and developmental toxicity
of THC and CBD using zebrafish as a highly relevant, predictive, and high-throughput
model. Specifically, we aimed to establish a zebrafish model for developmental exposure
to THC or CBD and scrutinize the resulting differential gene expression, developmental
deformities, behavioral alterations, and decreased reproductive success. Initially THC
was expected to have adverse side-effects on brain development and gamete viability,
but little was known about the toxicity of CBD. Our central hypothesis in Aims 1 and 2
was that developmental exposure to CBD or THC changes gene expression in critical
morpho-/neurogenesis genes during development that are, in turn, related to the origins
of adult disease.
Our experimental approach was accomplished in two research aims and one
analytical aim. Aims 1 and 2 are diagramed in Figure 1.2. Briefly, F0 fli transgenic
zebrafish were exposed to THC, CBD, or DMSO (Figure 1.5). Across the cannabinoid
dose-response, we measured morphological and behavioral abnormalities throughout
development and at a few time points on the whole transcriptome. Tissue- and
developmental-stage

specific

gene

expression

of

key

morphogenesis

and

neurodevelopmental genes hypothesized to be biomarkers of toxicity were measured at
multiple time points (14, 24, 48, 72, and 96 hpf) by RT-qPCR. After the initial 96 hr
exposure, fish were allowed to grow for 6 months with no further treatment. In adults, we
measured potentially compromised learning and anxiety behaviors (12-18 months; Aim
1) and reproductive success (6 months; Aim 2) The same morphological, behavioral, and
gene expression studies were carried out with F1 embryos at the same time points as F0.
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Aim 3 used zebrafish to develop a toxicokinetic model for cannabis exposures in an
aqueous medium. Extraction methods for plasma and urine are easily accessible (Kemp
et al., 1995) in many animal models; however, methods for extracting THC or CBD from
water using aquatic organisms was lacking.

Figure 1.5 Experimental flow chart. Embryos were collected at ~1 hpf and cleaned/sorted
into glass vials. Regardless of the exposure duration, all embryos were handled and
exposed similarly. 14, 24, 48, and 72 hpf time-points were analyzed for survival then
collected for RT-qPCR, while 96 hpf larvae were transferred to a 96-well plate and
screened for morphological and behavior abnormalities. Following morphological and
behavior screening, 96 hpf were also collected for RT-qPCR.
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Our overall goal of Aims 1 and 2 is to establish the continuum of THC and CBDmediated initiating event(s) followed by related anatomic and functional adverse
outcomes which, in turn, impact individual and population level incidences of disease
(Ankley et al., 2010). As is depicted in the Figure 1.1 AOP scheme, our plan was to
quantitatively assess biomarkers at the macromolecular, cellular, organ, organism and
population levels of biological organization in order to generate a mechanism-based
dose-dependent understanding of cannabinoid developmental toxicity.
The focus of this work was on the embryo-larval stage of development. There are
several logistical and physiological justifications for this initial focus. For example,
embryos are easy to expose and only small amounts of chemical are needed. Developing
organisms are especially susceptible to toxicants, and thus, statistically significant
alterations in gene expression and phenotype are easier to measure and causatively
associate during development. These studies will then inform future experiments where
more chronic exposure regimes and/or later developmental (e.g. puberty or adult
equivalent) stages could be exposed in order to align our approach more closely to model
epilepsy patients and other users of medical marijuana. To test our central hypothesis of
CBD toxicity we will conduct the following three specific aims:

1. Compare key gene expression, behavioral changes, and developmental
abnormalities in developing zebrafish and in their subsequent offspring.
Hypothesis: CBD and THC will alter gene expression in unique ways that
mechanistically support phenotypic defects. Differential gene expression will persist in
F1 offspring without additional exposure.
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Approach: Developmentally expose zebrafish embryos/larvae to CBD or THC and use
RT-qPCR to quantitate concentration-dependent, developmental stage- gene
expression in important neurodevelopmental and morphological genes in F0 and F1
fish at 14, 24, 48, 72 and 96 hpf. Measure developmental deformities and behavioral
changes in 96 hpf F0 & F1 larvae as well as F0 adult behavior.
2. Measure reproductive consequences of a developmental exposure to THC and
CBD.
Hypotheses: Developmental exposure to cannabinoids will compromise adult
reproductive success in a sex-dependent manner and gamete health will be dosedependently decreased after THC exposure. THC will be a more potent reproductive
toxicant as compared to CBD.
Approach: (a) Assess the hatching time, fertilization success, and mortality of F1
offspring from parents that were developmentally exposed to THC or CBD. (b)
Determine dose-dependent effects of cannabinoid developmental exposure on adult
fecundity.
3. Establish analytical toxicokinetic parameters for the conducting of water-based
cannabinoid exposures using zebrafish.
Hypothesis: THC and CBD will decrease over time in our static water exposure, but
increase over time in tissue (bioconcentrated).
Approach: (a) Establish a liquid:liquid extraction method for removing THC or CBD
from both water and tissue prior to GC-MS analysis. (b) Measure THC and CBD
concentrations in zebrafish embryo medium and whole tissue homogenate directly
following water dosing (time 0 hr) through experiment termination (time 96 hr).
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Successful completion of these aims will establish for the first time the potential
selective toxicity of THC versus CBD as a developmental, reproductive, and behavioral
toxicant. This work is highly relevant because human exposure to THC is known to cause
reproductive deficits including: pregnancy loss and sperm malformations (Lewis et al.,
2012; Nahas et al., 2002) and in children, brain development deficits and social disorders
(Crean et al., 2011; Solowij et al., 2012; Szutorisz et al., 2014; Tortoriello et al., 2014; Wu
et al., 2011). However, the developmental toxicity of CBD is unknown. Zebrafish are a
well-established model in developmental biology, toxicology testing, and increasingly
used for high-throughput screening in drug development (Feitsma and Cuppen, 2008; Hill
et al., 2005; Kalueff et al., 2014; MacRae and Peterson, 2015; Padilla et al., 2012; Pei
and Strauss, 2013; Tobia et al., 2013; Vitale et al., 2014). Through this work, we will gain
insight into the potential mechanisms mediating both cannabinoid toxicity and therapeutic
efficacy.
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CHAPTER 2 DEVELOPMENTAL EFFECTS OF CANNABIDIOL AND Δ9TRETRAHYDROCANNABINOL IN ZEBRAFISH
2.1 Abstract
Cannabidiol (CBD) has gained much attention in the past several years for its
therapeutic potential in the treatment of drug-resistant epilepsy, such as Dravet
Syndrome. While CBD has shown anecdotal efficacy in reducing seizure frequency, little
is known regarding the potential adverse side-effects of CBD on physiology,
development, organogenesis, or behavior. The goal of this chapter is to compare the
relative morphological, behavioral, and gene expression phenotypes resulting after a
developmental exposure to Δ9-tetrahydrocannabinol (THC) or CBD. Zebrafish were
exposed from blastula through larval stage (96 hour post fertilization) to 0.3, 0.6, 1.25,
2.5, 5 mg/L (1, 2, 4, 8, 16 μM) THC or 0.07, 0.1, 0.3, 0.6, 1.25 mg/L (0.25, 0.5, 1, 2, 4 μM)
CBD. Despite the similarity in THC and CBD dysmorphologies, i.e., edemas, curved axis,
eye/snout/jaw/trunk/fin

deformities,

swim

bladder

distention,

and

behavioral

abnormalities, the LC50 for CBD (0.53 mg/L) was nearly seven times lower than THC (3.65
mg/L). At 96 hpf, c-fos, dazl, and vasa were differentially expressed following THC
exposure, but only c-fos expression was significantly increased by CBD. CBD was more
bioconcentrated compared to THC despite higher THC water concentrations. This work
supports the potential for persistent developmental impacts of cannabinoid exposure, but
more studies are needed to assess latent effects and their molecular mechanisms of
toxicity.
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2.2 Introduction
Cannabidiol (CBD) has gained much attention in the past several years for its
therapeutic potential in the treatment of many ailments, including tragic forms of drugresistant epilepsy, such as Dravet Syndrome (Devinsky et al., 2017). Additionally, CBD
legalization is increasing in the United States due to potential therapeutic indications
ranging from depression, schizophrenia, chronic pain, and even cancer (McKenna, 2014).
Medical cannabis legalized states, such as Washington, currently offer over 800 CBD
products available for purchase, and CBD sales in the United States are projected to
reach $2.1 billion by 2020 (Murphy and Ooyen, 2016). Numerous studies suggest CBD
contains therapeutic potential (Cridge and Rosengren, 2013; Devinsky et al., 2017, 2014);
however, the toxicology community has yet to scrutinize its possible adverse effects. Most
importantly, CBD is currently being administered to toddler through adult aged patients of
Dravet Syndrome, with little empirical evidence of its potential developmental or
reproductive consequences. Moreover, CBD is perceived to possess a safer toxicological
profile than Δ9-tetrahydrocannabinol (THC) due to its weak affinity for cannabinoid
receptor 1 (CB1); therefore, lacking a psychotropic effect. This study aimed to define the
relative adverse developmental effects of CBD compared to the more well-known
cannabis constituent, THC, which does cause reported developmental, teratogenic, and
behavioral abnormalities (Akhtar et al., 2013; Becker et al., 2010a; Brunet et al., 2006;
Crane et al., 2013; Deiana et al., 2012; Fontes et al., 2011; Geber and Schramm, 1969;
Hisaoka, 1958; Hurd et al., 2005; Maccarrone and Finazzi-Agro, 2004; Paria et al., 1995;
Ruhl et al., 2014; Stewart and Kalueff, 2014; Thomas, 1975; Wright et al., 1976).
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The EDC and its corresponding G-protein coupled receptors, CB1 and CB2, are
critical for early development and central nervous system maturation (Psychoyos et al.,
2012). Disruption of the EDC can effect early developmental stages leading to
dysmorphologies, embryotoxicity, behavioral abnormalities, memory deficits, and
adverse neurogenesis in zebrafish, chick, rodents, and humans (Harbison et al., 1977;
Paria et al., 1995; Psychoyos et al., 2012; Watson et al., 2008). Distribution of
cannabinoid receptors differ; in vertebrates CB1 is currently thought to primarily
concentrate in the central and peripheral nervous systems while CB2 is primarily
expressed in the immune system (Lam et al., 2006; Pertwee, 2006). Although much
debate encompasses the individual actions of CB1 and CB2 signaling, CB1 receptors
have been connected to cardiovascular activity, neuroplasticity, olfaction, and GABA(A)
signaling (Tortoriello et al., 2014). CB2 functions are less known, but include immune
regulation and potential adversities related to neurodegeneration (Szaflarski and Martina
Bebin, 2014). The EDC amongst mammals and zebrafish is highly conserved (Krug and
Clark, 2015). Whole-larval homogenate has shown CB1 mRNA expression present during
the 3 somite stage through the 25 somite stage (B. Migliarini and Carnevali, 2009), while
whole-mount in situ hybridization localized CB1 mRNA throughout the zebrafish brain
with highest expression in the telencephalon at 96 hpf (Lam et al., 2006). In addition, CB1
protein has been observed in both larval zebrafish brain homogenates beginning around
48 hpf through 15 days post fertilization (B. Migliarini and Carnevali, 2009). CB2 has also
been detected throughout the adult zebrafish gills, heart, retina, intestine, spleen, brain,
and pituitary, less is known regarding CB2’s expression patterns throughout development
and adolescence (I. Rodriguez-Martin et al., 2007).
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Signal transduction with regard to THC, CBD, and the EDC are still under
investigation; however, an important mechanistic role in the propagation and
maintenance of seizures in animal models and humans has been reported (Consroe et
al., 1982, Consroe & Wolkin, 1977, Devinsky et al., 2017, & Jones et al., 2010). The
primary exogenous ligand of CB1 is THC; however, CBD has low affinity for CB1. Instead
CBD preferentially binds to CB2 and may actually possess antagonistic properties toward
CB1 (Schönhofen et al., 2015). Because of the recognized roles of endogenous ligands
such as 2-AG , AEA, and the cannabinoid receptors in neurodevelopment (reviewed in
Basavarajappa et al., 2009), it is imperative to uncover possible mechanisms of CBD
and/or THC toxicity during essential stages of neurodevelopment and organogenesis.
Dating back to the 1960’s, animal models have been used to elucidate cannabinoid
toxicity (Persaud and Ellington, 1968). Primary literature has focused on prenatal and
postnatal exposure in rodents via oral or subcutaneous injection measuring various
endpoints from behavior and endocrine function to neuropathology (Scallet, 1991).
Adverse outcomes in rodents of developmental exposure include craniofacial (Bloch et
al., 1986) and behavior abnormalities (Onaivi et al., 1995; Wright et al., 1976) similar to
those reported in zebrafish (Akhtar et al., 2013; Thomas, 1975), but very few publications
offer insight into CBD toxicity. Recent literature has primarily focused on the protective
and therapeutic potential of CBD; however, some results suggest that CBD exposure
during neuronal development might lead to sensitization to neurotoxicants (Schönhofen
et al., 2015). Rats and adult zebrafish were used to demonstrate CBD’s behavior
abnormalities (Nazario et al., 2015a; Resstel et al., 2009), but little information has been
offered with regard to developmental adversities, potential onset of adult disorders, or
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early neurogenesis and maturation which may result from a teratogenic or pediatric
exposure.
The goal of this project was to use the highly relevant zebrafish model to study the
potential morphological and behavioral toxicities of CBD compared to a known
developmental toxicant, THC (Akhtar et al., 2013; Thomas, 1975). Developmental
biomarkers were also screened to elucidate potential mechanistic roles. Additionally, we
provide evidence that via water-based exposures, lipophilic cannabinoids (THC log P:
6.97; CBD log P: 5.79) bioaccumlated in fish embryos (Thomas et al., 1990) and caused
developmental toxicity.

2.3 Material and Methods
2.3.1 Zebrafish Care and Exposure
Tg(fli1:egfp) zebrafish were purchased from Zebrafish International Resource
Center (ZFIN, Eugene, Oregon). Healthy adult zebrafish were placed in aerated breeding
units containing water from an Aquatic Habitats Zebrafish Flow-through System (Aquatic
Habitats, Apopka, Florida), pH 7.5-8.0, dissolved oxygen 7.2-7.8 mg/L, conductivity 730770 μS, temperature 27°-29°C. The next morning, eggs were collected, debris removed,
and randomly sorted into scintillation vials (n = 3 vials; 10 embryos per vial) containing
embryo water (sterilized deionized water; pH of 7.4-7.7; 60 parts per million (ppm) Instant
Ocean, Cincinnati, Ohio). Scintillation vials were then placed into a stand-up incubator at
27°-29°C. Exposed eggs were screened every 24 hours to assess overall health and to
remove any dead embryos. All culture and exposure protocols were in accordance with
approved IACUC guidelines and recommendations. At ~2 hpf, original transfer water was
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removed and replaced with 0.3125, 0.625, 1.25, 2.5, 5 mg/L (1, 2, 4, 8, 16 μM) THC
(0.05% DMSO), 0.075, 0.15, 0.3, 0.6, 1.2 mg/L (0.25, 0.5, 1, 2, 4 μM) CBD (0.05%
DMSO), or 0.05% DMSO control water. Embryos were exposed in scintillation vials at a
0.6:1 (mLs water:fish) ratio in static conditions without a water change during the
exposure period. Every 24 hours, mortalities, debris, and sloughed chorions were
removed from vials. THC and CBD were provided by the NIDA Drug Supply Program
(DEA License #RW0497796).

2.3.2 Morphological and Behavior Screening
At 96 hpf, larvae were transferred from scintillation vials into 96-well plates (one
larvae per well). Touch response, yolk sac and pericardial edema, axis curvature,
eye/snout/jaw/trunk deformities, swim bladder inflation, and pectoral fin dysmorphologies
were all qualitatively analyzed single-blinded as either deformed (yes) or not deformed
(no). LC50 values were calculated using the EPA’s LC50 calculation program at the
conclusion of the 96 hpf assessment (Hamilton et al., 1977). Lowest observed adverse
effect levels (LOAELs) were calculated as a 20% dysmorphologic occurrence greater
than controls (e.g. if curved axis occurrence in control fish was 5%, the LOAEL
concentration = ≥ 25% curved axis occurrence). Following morphological screening,
zebrafish with a touch response were directly transferred to an isolated behavioral
screening room kept in full light at 27°-29°C and allowed to acclimate for 5 minutes. Touch
response was assessed by touching the larvae’s tail with the end of a 10 μl pipette tip.
Larvae either reacted to the mechanical impact by avoidance swimming or did not
respond. Zebrafish were then monitored using a ViewPoint ZebraBox (ViewPoint,
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Montreal, Canada) for 30 minutes (0-10 min, 100% light (8000 lux); 10-20 min, dark, 0%
light; and 20-30 min, 100% light) (Kirla et al., 2016). Travel duration at a velocity ≥5
mm/sec was collected per well and averaged per dosing parameter. Duration mean for
each pooled vial was calculated and statistical significance was calculated per vial (n =
3) using two-way analysis of variance with repeated measure followed by Bonferroni post
hoc test (p ≤ 0.05) (n = 3 replicates; 7-10 larvae per replicate for morphology screen and
n = 6 – 30 for behavioral screens). THC (1.25 mg/L) and CBD (0.3 mg/L) were excluded
from statistical analysis due to a lack of fish (n < 3) healthy enough to perform in the
behavioral analysis; however, they are still depicted in Figure 2.

2.3.3 RT-qPCR
Following the behavioral screen, larval zebrafish were pooled (n = 3 vials; 10 fish
per vial) in RNAlater and stored at -80°C until RNA isolation and processing. Whole larval
RNA was isolated utilizing TRIzol (Invitrogen #A33251), RNase-Free DNase set (Qiagen
#79254), and RNeasy micro kit (Qiagen #74004) according to manufacturer’s protocol.
Extracted RNA was then quantified and assessed for acceptable 260:280 ratio on a
NanoDrop 2000 followed by cDNA (10 μg/μL) sub-stock preparation (Invitrogen
#4304134). RT-qPCR was performed on an Applied Biosystems 7200 using SYBR Green
chemistry (Applied Biosystems #4309155) with the following parameters: 95°C for 10 min,
then 40 cycles of 95°C for 15 sec and 60°C for 1 min, followed by 95°C for 15 sec-60°C
for 1 min-95°C for 15 sec dissociation curve. Primer optimization and confirmation was
performed as previously described in Fang et al., 2013. Final concentrations in the
reaction mix were: forward and reverse primer 0.2 μM, template cDNA 0.4 ng/μL, and
43

SYBR Green PCR Master Mix according to manufacturer’s protocol (Applied
Biosystems). All samples (n = 3) were screened in duplicate and evaluated using the 2ΔΔCT

method (Livak and Schmittgen, 2001). RT-qPCR results were analyzed using three

pooled (10 fish) homogenate biological replicates (n = 3). For statistical significance, we
used one-way analysis of variance followed by Tukey’s post hoc test with statistical
significance being met at p ≤ 0.05. Additional RT-qPCR information available in
Supplemental Table 2.1.

2.3.4 GC-MS Analysis
In order to confirm exposure concentrations and better understand the exposure
kinetics of THC and CBD, water and tissue concentrations were verified at 0 hpf (T i) and
96 hpf (Tf), as previously described (Kudo et al., 1995). Briefly, deuterated THC-d3 (Sigma
Aldrich) was added to 2 mL (10 mg/L) of exposure water along with 1 mL of 2 M NaOH
followed by a solvent:water extraction using hexane:ethyl acetate (9:1, v/v) repeated two
times. Once in solvent, samples were evaporated to dryness using nitrogen in a water
bath

at

55°C.

Samples

were

then

reconstituted

and

derivatized

in

N,O-

Bis(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorosilane (Thermo Scientific) at
90°C for 1 hour. Following derivatization, samples were evaporated to dryness and
reconstituted in 50 μL isooctane and transferred directly to the GC-MS (Agilent
Technologies 6890N; Mass Spectrometer 5973) with DB-5MS column (Agilent
Technologies) for analysis as previously described (Kemp et al., 1995). Retention times
and ions [quantitatve;qualitative] for quantifying THC-d3, THC, and CBD were as follows:
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8.142 min [374;389 m/z], 8.167 min [386;371 m/z], and 6.936 min [390;458 m/z]. Our
lowest observed quantifiable concentration was 8 μg/L THC and 19 μg/L CBD.
For tissue extractions, dry larvae were weighed and then homogenized in
hexane:ethyl acetate (9:1, v/v) (containing THC-d3) with 100 pulses of a teflon pestle.
Following homogenization, extractions were evaluated as described above for water.
Measured water and tissue concentrations of THC or CBD were calculated using a
relative response factor derived from the surrogate standard recovery (e.g. [initially
measured THC or CBD concentration/surrogate standard recovery]). Bioconcentration
factors were calculated by dividing the measured concentration of compound in tissue
samples at 96 hpf by the measured concentration of compound in exposure water at 0
hpf, bioconcentration factor (BCF=Ctissue(Tf) / Cwater(Ti)). To measure extraction recoveries
pooled whole zebrafish larvae (n = 10 per replicate; 2-10 replicates) at 96 hpf and
hexane:ethyl acetate (9:1, v/v) were spiked with 10 mg/L THC, CBD, or THC-d3, and then
extracted as described above. Recoveries were calculated by comparing the area under
the curve (AUC) of ion peaks to a non-extracted standard curve 0.016 mg/L to 50 mg/L
for each compound. Recoveries were as follows: THC 83.7 ± 11.6%; CBD 54.2 ± 0.14%;
and THC-d3 65.5 ± 8.6%.

2.3.5 Statistics
All statistical analysis was analyzed in GraphPad Prism 5.0. Data analysis included
as appropriate, normal theory (e.g. ANOVA) and/or non-parametric (e.g. Kruskall-Wallis)
procedures to test treatment-related effects. Behavioral phenotypes were analyzed using
two-way ANOVA with repeated measures followed by Tukey’s post hoc test. In the event
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of RT-qPCR not achieving statistical significance after one-way ANOVA and Tukey’s post
hoc analysis, data was subjected to an unpaired student’s t-test. p < 0.05 will be used as
the cut-off for statistical significance.
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Table 2.1 RT-qPCR Primers
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Gene

Accession

c-fos

BC065466

dazl

BC076423

vasa

AF461759

sox2

BC065656

sox3

AB117960

sox9a

BC093134

krit1

BC055149

bdnf

BC058301

reln

JF693485

cnr1

AY148349

cnr2

AY263391

18s

FJ915075

Primer sequence
F: 5'-CAC CGA TAC ACT GCA AGC TGA A-3'
R: 5'-CAG GTT GGC GAT GTC GTT CT-3'
F: 5'-AAT GCC CAG CTT GCC TAA TG-3'
R: 5'-CAC GCG GCC GAA ACC-3'
F: 5’-CAG ACA AGT TGG ATC AAG AAG GAA-3’
R: 5’-GGC GGC GGC ACA TAA AC-3’
F: 5'-ACC AAC TCG CAG ACC TAC ATG A-3'
R: 5'-GCG TGC TTT GCT GCG AAT-3'
F: 5'-CCG GCC ATA ACC TCT CAC TCT-3'
R: 5'-GGC GGC AGG TAC ATG CTT-3'
F: 5’-CAT CCC TCA ATC CAA CCA CAG-3’
R: 5’-GGT CTG GAC AGC TGC GTG TAC-3’
F: 5’-CAT AAT AGG GAA GCG TGT TGT G-3’
R: 5’-GGA GGA GAA ATG AGC ACT GG-3’
F: 5’-GAC TCG AAG GAC GTT GAC CTG TA-3’
R: 5’-CGG CTC CAA AGG CAC TTG-3’
F: 5’-TTC TAC TGC CCC TAC CAG AGA G-3’
R: 5’-AAT CTC GAG AAA ACT CCA GAC G-3’
F: 5’-TGT GGG AAG CCT GTG TTC TCA CT-3’
R: 5’-CGA TGC GCC GGT ACG A-3’
F: 5’- TCT AGC CGG CCC AGT GAC T-3’
R: 5’- GTG CTG TGG AGC TTG CAA TG-3’
F: 5'-TGG TTA ATT CCG ATA ACG AAC GA-3'
R: 5'-CGC CAC TTG TCC CTC TAA GAA-3'

r2

Efficiency
%

0.997

106.2

0.974

84.06

0.971

92.35

0.988

100.42

0.999

94.99

0.938

87.08

0.992

75.8

0.977

97.95

0.930

84.12

0.920

86.36

Not functional
0.999

75.61

2.4 Results
2.4.1 Water and Tissue Analysis
Actual THC concentrations in water at Ti (0 hpf) were between 64-88% of
expected and declined to between 16-32% of Ti at 96 hpf (Tf) (Table 1). Actual CBD
concentrations were only 33-40% of nominal at Ti and decreased to either not detected
or 3% of Ti at Tf (Table 2.2). THC and CBD tissue concentrations were assessed at 96
hpf following homogenization and solvent extraction. Following 96 hpf exposure to 0.313
or 1.24 μg/mL THC, the calculated BCF’s were approximately 1.4 and 0.65, respectively
(Table 2.2). Following 96 hpf exposure to 0.075 or 0.3 CBD, the calculated BCF’s were
39 and 790, respectively (Table 2.2). After 96 hr of exposure to nominally 0.3 μg/ml THC
or CBD, tissue concentrations in larvae were 0.28 μg/g and 79 μg/g, respectively.
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Table 2.2 Water and Tissue Concentrations.
Compound

hpf

μg/mL

Measured
Water
Concentration
μg/mL ± SD

0a
0.313
1.25
0a
0.313
1.25

nd
0.2 ± 0.01
1.1 ± 0.2
nd
0.05 ± 0.008
0.4 ± 0.03

64
88
16
32

0.01 ± 0.0
0.007 ± 0.001
0.001 ± 0.008

nd
0.28 ± 0.14
0.71 ± 0.72

1.4
0.65

0a
0.075
0.3
0a
0.075
0.3

nd
0.03 ± 0.01
0.1 ± 0.03
nd
nd
0.01 ± 0.004

40
33
3

0.003 ± 0.003
0.002 ± 0.0
0.003 ± 0.001

nd
1.2 ± 0.16
79 ± 51

39
790

Nominal Water
Concentration

% Nominal

Fish Massb

Measured Tissue
Concentration

g ± SD

μg/g ± SD

BCFc

Δ9Tetrahydrocannabi
nol
0

96
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Cannabidiol
0

96

nd = not detected
a Control (0.05%
DMSO)
b 3 - 7 larvae
c BCF = C
tissue(time 96) / Cwater(time 0)

2.4.2 Lethality and Morphology
Following a waterborne exposure to CBD and THC, 96 hpf zebrafish displayed
concentration-dependent morphological (Figure 2.1) and behavioral toxicities (Figure
2.2). The CBD LC50 of 0.53 mg/L was nearly seven times lower than that of THC (3.65
mg/L). CBD and THC shared similar adverse morphologic outcomes, i.e., yolk sac and
pericardial edema, pectoral fins missing, and swim bladder distention; however, the
LOAEL for these observed dysmorphologies varied (Figure 2.1). For example, the LOAEL
for pericardial edema following THC exposure was approximately 0.6 mg/L, while CBD
was more than ten times lower at 0.07 mg/L (Figure 2.1). Similarly, LOAELs for jaw
malformations (5 mg/L THC, 0.3 mg/L CBD), axis curvature (2.5 mg/L THC, 0.6 mg/L
CBD), and trunk degradation (2.5 mg/L THC, 0.6 mg/L CBD) were all lower in CBD
exposed larvae compared to THC.
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Figure 2.1 THC and CBD morphologic phenotypes. Following 96 hpf exposure to THC or
CBD larvae were plated in 96-well plates (one per well) and qualitatively assessed for
common developmental dysmorphologies. All morphology endpoints were designated
either a yes (abnormal) or no (normal) and quantitatively calculated from the total larvae
measured for both THC (A) and CBD (B). Higher concentrations with 100% occurrence
in all endpoints are depicted. Subsequent phenotypical pictures were taken following the
morphology screening (C), red arrows indicate a few key morphologic endpoints (T =
trunk, A = axis, SB = swim bladder, P = pericardial edema, Y = yolk sac edema). In
addition to phenotypic malformations following 0.6 mg/L CBD exposure, we also observed
numerous 96 hpf larvae that were unhatched. Heat-map portrayal (D) of the LOAEL after
96 hpf exposure to THC and CBD (n = 3 replicates consisting of 10 fish per replicate).

51

2.4.3 Behavior
Behavior is assessed via movement during dark conditions compared to bright light
conditions. Typically, zebrafish larvae exhibit hyperlocomoter behavior during dark
periods and hypolocomoter behavior during bright conditions, especially during initial
cycling periods (Kirla et al., 2016). Larvae exposed to 0.3 mg/L THC or 0.07 mg/L CBD
exhibited a significantly increased duration of movement (seconds of duration ≥ 5
mm/sec) during dark periods compared to control. In contrast, 1.25 mg/L THC and 0.10.3 mg/L CBD significantly reduced duration compared to control, which is indicative of
hypolocomoter activity (Figure 2.2). All duration times were compared using two-way
ANOVA with the Bonferroni post-test ± SEM. All larvae lacking a touch response or
phenotypically not able to swim were excluded from behavioral assessment; therefore,
high concentrations of compound tended to result in smaller sample sizes (n = 6-30)
which lead to increased standard errors. However, even with increased error, larvae
exposed to 1.25 mg/L THC still exhibited significantly decreased duration during dark
periods compared to control larvae (minute 16; Figure 2.2).
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Figure 2.3 Larval zebrafish behavioral heat map. Larval zebrafish behave in a consistent
manner when subjected to alternating light phases. Hypolocomotor activity is a result of
a normal phenotype during lit periods (top), while hyperlocomoter activity is a normal
phenotype during dark periods (bottom). The tracking lines of the ZebraBox allow us to
discern between different velocities of movement, i.e., inactive (black), slow (green), and
fast (red).
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Figure 2.2 THC and CBD larval behavior. Zebrafish larvae at 96 hpf were monitored using
a ViewPoint ZebraBox for 30 minutes (0 – 10 min, light: 10 - 20 min, dark (grey box): 20
– 30 min, light). Duration of movement (seconds) at a velocity ≥ 5 mm/sec was collected
at 2 min intervals and compared to control. Behavioral assessment was specific only to
larvae displaying a touch response and uninhibited phenotypes; therefore, the full range
of concentrations-response is not available. Larvae exposed to 0.3 mg/L THC exhibited
significant (*) hyperlocomoter activity compared to control in dark periods (minutes 1220); however, 1.25 mg/L THC reduced overall duration of movement at minute 16.
Similarly, CBD significantly stimulated locomotor activity at 0.07 mg/L, but larvae exposed
to 0.1 and 0.3 mg/L CBD exhibited hypolocomoter characteristics. Data were analyzed
on the average distance per vial (n = 3) using two-way ANOVA with repeated measure
followed by Bonferroni post-test ± SEM (p ≥ 0.05). (n = 3 vials; 7-10 larvae per vial).
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2.4.4 RT-qPCR
Following a 96 hpf exposure to THC or CBD, larval zebrafish were screened for
potential differential expression of ten key morphogenic or neurogenic genes. c-fos was
differentially

up-regulated

in

a

concentration-dependent

manner

following

a

developmental exposure to both THC (1.25 and 2.5 mg/L) and CBD (0.07 and 0.1 mg/L)
(Figure 2.3). THC (0.3, 0.6, 1.25, and 2.5 mg/L), but not CBD exposure, resulted in dazl
up-regulation (Figure 2.3). In addition, expression of vasa, sox2, sox3, sox9a, bdnf, reln,
krit1 and cannabinoid expressing gene cnr1 was measured; however, no statistically
significant differential expression of these genes compared to control was detected.

55

Significant (+) differential gene expression after 96 hpf
exposure to THC or CBD
THC/CBD
↑/↑
c-fos
dazl
↑/vasa
↓/Morphogenesis
sox2
-/sox3
-/sox9a
-/krit1
-/bdnf
-/reln
Neurogenesis
-/cnr1
-/-

Figure 2.3 THC and CBD gene expression. Differential expression via RT-qPCR of 10
genes, as compared to reference gene 18s, following a 96 hpf developmental exposure
to THC, CBD, or DMSO. (↑/-) represents significance (p < 0.05) using ANOVA and
Tukey’s post-hoc test (n=3). c-fos was differentially expressed in a concentrationdependent manner in both THC and CBD exposed larvae, while dazl and vasa were only
differentially expressed by THC. CBD is depicted in only two concentrations due to LC50
limitations. (Bars with the same letter are not significantly different).
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2.5 Discussion
An important result of this study was that similar concentration-dependent
morphological and locomotor behavioral outcomes following a 96 hpf developmental
exposure to both CBD and THC were observed. Zebrafish larvae exposed to THC
displayed very similar adverse outcomes to those previously published (Akhtar et al.,
2013; Thomas, 1975). Toxicities included pericardial/yolk sac edemas and curved axis as
well as increased locomotor activity at low concentrations of THC; however, implications
for larval morphology and behavior following CBD exposure was previously unknown.
CBD exposure at blastula through larval stage increased developmental
dysmorphologies, especially jaw malformation, at relatively lower LOAELs (0.3 mg/L) than
THC (5 mg/L). Previously embryo abnormalities such as craniofacial deformities have
been reported in rodents following gestational exposure to THC (Bloch et al., 1986;
Harbison et al., 1977; Rosenkrantz, 1999). A/J strain mice exposed to as little as 60 mg/kg
THC between gestational days 11-14 experienced increased frequency of cleft palate
(Bloch et al., 1986). These results were also found previously using Swiss-Webster mice
at much higher doses of THC (300 mg/kg) (Harbison et al., 1977). While numerous
studies have been conducted on THC developmental abnormalities in rodents; doses,
routes of administration, and species differences vary. For example, newborn albino rat
fetuses experienced few abnormalities when parents were exposed prior to mating to low
concentrations of THC (0.5 – 5 mg/kg) (Wright et al., 1976). Comparative studies have
been conducted relating development genes during early morphologic stages in the
mouse (embryonic day 12) and zebrafish (48 hpf) models (Wullimann and Meuller, 2004).
Additionally, genes such as sox9 have been implicated in craniofacial deformities in both
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zebrafish (Yan et al., 2005) and mice (Bi et al., 2001), but in our study differential gene
expression of sox9 was not detected in 96 hpf THC or CBD-treated larvae.
An additional endpoint that significantly differed between CBD and THC was the
relative LOAELs for pericardial edema. The THC LOAEL for pericardial edema (0.6 mg/L)
was roughly ten-times higher than CBD (0.07 mg/L). Enlarged pericardium in larval
zebrafish can be caused by a number of attributes, including deregulated cardiovascular
development-oriented genes (krit1), heart failure, or morphologies related to improperly
placed heart chambers (Chen et al., 1996). In mice, research has shown krit1 mutations
were present in cerebral cavernous malformations which encompassed vascular lesion
irregularities, although no connection to cardiovascular morphology was present in
current literature (Wüstehube et al., 2010). However, we did not observe differentially
expressed krit1 in 96 hpf whole larval homogenates. This result could be attributed to time
specific-differential expression that should precede cardiovascular adverse outcomes;
future work should assess gene expression at multiple developmental time-points.
Acute effects of THC on the cardiovascular system range widely from increased
heart rate, blood pressure, and cardiac output to hypotension (Jones, 2002); however,
whether these endpoints directly affect embryo cardiovascular health is still under
investigation. Zebrafish pericardial edema morphologies relate to a detrimental toxic
event during imperative stages of development (somite 21-26; ~19-22 hpf) (Kimmel et al.,
1995; Stainier and Fishman, 1992) and have been studied widely in conjunction with
known developmental toxicants (Corrales et al., 2014b; King Heiden et al., 2009). More
studies are needed in order to identify the underlying molecular initiating events for these
toxicities and whether pericardial edemas caused by cannabinoids are the manifestation
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of functional cardiovascular abnormalities, signal transduction hindrance, or a
combination of the two. Per our results, cnr1 mRNA expression was not differentially
expressed compared to control following THC or CBD exposure; however, additional
knockout studies are needed to elucidate the extent of cannabinoid receptor involvement
in initiating morphologic or behavioral phenotypes.
Molecular reporters for morphogenesis or neurogenesis aberration were a point of
focus due to the observed organogenesis and behavioral changes in exposed fish. bdnf
and rln are both imperative for normal brain development and function, for example, bdnf
differential expression has been observed in patients with Parkinson’s disease,
Alzheimer’s disease, and dementia while rln assists in neuronal cell migration during brain
development (Fatemi et al., 2005; Vairo et al., 2015). We did not find any significance in
bdnf or rln expression following THC or CBD exposure, but will continue to explore the
possible ramification of cannabinoids on brain development and adult onset of
neurological disorders in zebrafish. vasa, sox2, and sox3 have been previously studied
in our laboratory as potential markers of impaired organogenesis or embryogenesis
(Corrales et al., 2014a; Fang et al., 2013) and are important molecular biomarkers for
assessing the adverse reproductive effects of cannabis exposure. While we observed no
differential expression in sox2 and sox3, vasa expression was decreased between the
0.3 and 1.25 mg/L THC treatments (Figure A2.1), but not statistically different than
control. vasa is highly expressed in spermatocytes as well as mature oocytes and is highly
conserved in both invertebrates (e.g. Drosophila) and vertebrates (e.g. Xenopus, chick,
mouse, and human) during germ cell development (Raz, 2000).
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Behavioral abnormalities following acute and chronic exposure to THC are well
established in both rodents and zebrafish (Akhtar et al., 2013; Champagne et al., 2010;
Long et al., 2010; Rodríguez et al., 2017). Neonatal THC exposure to C57/BL6 mice
caused neurotoxicity during early developmental periods leading to schizophreniasuggestive behavior in early adult-hood (Rodríguez et al., 2017). CB1-knockout mice
have increased anxiety-like behavior and more aggressive tendencies than wild-type
which indicates possible CB1-mediated anxiogenic properties when disrupted (Haller et
al., 2004). Zebrafish have conserved behavior to rodents following THC exposure
(Champagne et al., 2010). Following developmental low-concentration THC exposure,
zebrafish exhibit an increased locomotor activity, but increased concentrations have a
normalizing effect (Haller et al., 2004). Our results indicate similar neurotoxic effects
following THC and CBD exposure. Whether or not these results represent anxiogenic-like
behavior requires further analysis. Stress or anxiogenic-like behavior in larval zebrafish
is usually represented by a reversal in characteristic light:dark behavior (Ellis et al., 2012).
We observed hypolocomoter activity in light periods at high concentrations in both THC
and CBD, but also observed hypolocomoter activity during dark periods which suggests
a neurotoxic event in neuronal connectivity possibly void of stressful/anxiogenic
properties (Kim et al., 2013). We did find concentration-dependent increases in c-fos
expression, which is correlated to increased neural activity and hyperlocomoter behavior
in zebrafish (Baraban et al., 2005; Morgan et al., 1987). Our initial hypothesis predicted
CBD to significantly reduce c-fos expression in correlation with hypolocomoter behavior
due to its anti-convulsant indications (Devinsky et al., 2017); however, both THC and CBD
upregulated c-fos in a manner that was inconsistent with behavioral outcomes. This
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outcome may be due to a neurotoxic event affecting molecular signaling and behavioral
phenotypes.
Another major goal of this study was to study the basic pharmacokinetic/
toxicokinetic characteristics of a cannabis waterborne exposure scenario. While zebrafish
is an established model for assessing developmental toxicities (Henry et al., 1997) and
behavioral phenotypes (Nazario et al., 2015a), water-based exposures require water
concentration and tissue bioconcentration validation. With advancements of CBD
cultivation and pharmaceutical application, it is imperative to formulate a model that meets
very high standards for both organismal translatability and high-throughput potentiality.
Prior studies have subjected adult zebrafish to intraperitoneal (i.p.) injections of CBD,
which is very time consuming and not applicable for high-throughput applications. In
addition, the utilization of i.p. injections while assessing locomotor characteristics may not
be suitable for the sensitive nature of behavioral or developmental screenings. Hence,
waterborne exposures are less time-consuming and place less stress on the organism
prior to analysis.
Previous studies have documented developmental toxicities without providing
confirmation of cannabinoid concentrations in water or proof of whether or not
cannabinoids are concentrated in larvae tissue during the exposure period (Akhtar et al.,
2013; Thomas, 1975). We found that CBD, even when used at much lower concentrations
than THC, tended to bioconcentrate in tissue. While this is counterintuitive due to the
higher polarity of CBD and lower log P compared to THC, the significantly lower CBD
LD50 may be attributed to bioconcentration rather than potency.
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This study provides a comprehensive morphological and behavioral assessment
following developmental exposure to THC and CBD. CBD is currently chronically
accessible to toddler epilepsy patients, hence, proper vetting of developmental and
reproductive toxicities is needed and can be accomplished in part with the zebrafish
model. A goal of this project moving forward is to further enhance our knowledge of THC
and CBD reproductive and multi-generational toxicities. Differentially expressed dazl hints
toward potential germline deregulation which may hinder reproductive fitness in the
exposed F0 (Takeda et al., 2009). Because of the relatively conserved neuroanatomy,
including cannabinoid receptor 1 signaling and behavior between zebrafish and
mammals, linking molecular to organismal responses will be highly translatable to
humans (Champagne et al., 2010; Krug and Clark, 2015; Lam et al., 2006; Panula et al.,
2010; Ivan Rodriguez-Martin et al., 2007; Schmidt et al., 2013; Stewart et al., 2014)dt et
al., 2013; Stewart et al., 2014). This study is foundation for future work, especially
considering the role of cannabis as a therapeutic in the holistic and pharmaceutical
industries (Bostwick, 2012).

2.6 Conclusion
Our investigation of CBD toxicity is highly relevant to a wide range of medical fields
of research including toxicology, epilepsy, and cancer (Blair et al., 2015; Cridge &
Rosengren, 2013). Initially, we hypothesized CBD would be the less toxic cannabis
constituent compared to THC primarily due to its non-psychotropic properties and weak
CB1 affinity; however, CBD mirrored THC developmental and behavioral toxicities at
strikingly lower concentrations. Additionally, CBD bioconcentrated more readily than THC
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regardless of its lower log P. Because of the developmental toxicities that we detected
and the overwhelming outcry for novel cannabis-based therapeutics, more research is
necessary to elucidate the molecular mechanisms and potential downstream EDC targets
or unrelated EDC off-target effects that may contribute to neurological or developmental
basis for both developmental and adult onset disease.
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CHAPTER 3 ASSESSING CANNABINOID DEVELOPMENTAL AND REPRODUCTIVE
TOXICITY IN ZEBRAFISH
3.1. Abstract
The legalization of recreation and medicinal Cannabis sativa is on the rise;
therefore, exposure rates among the infant, adolescent, and adult populations are
increasing. While Δ9-tetrahydrocannabinol (THC) has been widely studied in the realm of
developmental and reproductive toxicology, few studies have investigated potential
toxicities from a second widely used cannabis constituent, cannabidiol (CBD). CBD is
currently being popularized for its therapeutic potential for reducing seizure frequencies
in a catastrophic form of epilepsy, Dravet Syndrome. Dravet syndrome afflicts roughly
1:16,000 individuals, most of which are diagnosed as infants. Patients often run out of
treatment options due to Dravet syndrome’s drug-resistant characteristics; therefore,
many turn to alternative medicines, such as CBD. This study investigated the
developmental origins of health and disease (DOHaD) by quantitating multigenerational
gene expression patterns, behavior phenotypes, and reproductive fitness of a subsequent
F1 generation following an F0 developmental exposure to concentrations of THC or CBD
below the lowest observed adverse effect level (LOAEL), 0.024, 0.12, 0.6 mg/L (0.08, 0.4,
2 μM) THC, 0.006, 0.03, 0.15 mg/L (0.02, 0.1, 0.5 μM) CBD, or 0.05% DMSO control in
zebrafish. During key developmental stages, THC and CBD caused differential
expression of c-fos, brain-derived neurotrophic factor (bdnf), and deleted-in-azoospermia
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like (dazl), while only CBD differentially expressed dazl in F1 larvae at 48 and 96 hours
post fertilization (hpf). In addition, THC reduced larval light:dark behavior in both exposed
F0 and unexposed F1 larvae. Following THC and CBD exposure, fecundity was reduced
in a concentration dependent manner. This research outlines a need for future work
related to CBD toxicities, especially when considering possible ramifications from earlylife exposure.

3.2. Introduction
As cannabinoid exposure increases among the United States population, whether
for recreational or medicinal purposes, it is important to delineate potential hazards
associated with its use. This is especially crucial for understanding the developmental
origins of health and disease (DOHaD). Recent literature lacks empirical evidence of
cannabinoid toxicities during periods at which adverse outcomes may lead to embryo
toxicities, neurodevelopmental delay, adult disease, or possibly negatively affect
reproductive outcomes and pose a risk to offspring following parental exposure. Currently,
29 states have passed medical marijuana legislation within the United Sates; however, a
number of additional states possess laws specific for CBD drug trials and regulate the
way in which patients obtain medical cannabis (ProCon.org, 2017). While a previous
study revealed roughly fifty percent of medical cannabis users are below the age 35,
strikingly few demographic statistics are available concerning physician-related
prescriptions to young patients (Nunberg et al., 2011). Moreover, a recent trial
collaboratively

conducted

by

several

top-tier

medical

institutions

and

GW

Pharmaceuticals treated roughly sixty drug-resistant epilepsy patients with a mean age
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of 9.7 years old and as young as 2.5 years old with CBD (Devinsky et al., 2017). It is of
great importance to patients, doctors, and the toxicology community to research the
potential DOHaD following cannabis exposure during early-life stages and through critical
developmental periods.
THC and CBD have been widely used for several millennia to relieve multiple
indications

including

insomnia,

pain,

nausea,

satiety,

and

recently

seizure

frequency/severity (Bostwick, 2012). The latter is cause for concern due to the patient’s
age, which can be as young as 2 months (Lindsey, 2016). THC has previously been
implicated in developmental and reproductive toxicities. For example, early research in
rodents and humans following chronic use, resulted in adverse effects on
neurodevelopment, cognitive ability, and even adverse reproductive effects such as
spermatogenic apoptosis (Costa et al., 2015; Nahas et al., 2002; Rodríguez et al., 2017;
Schönhofen et al., 2015; Tortoriello et al., 2014; Wu et al., 2011). Very few studies have
focused on CBD’s safety profile; however, our recent work has depicted similar related
toxicities between THC and CBD in zebrafish (Carty et al., 2017). These related toxicities
include:

morphologically

deformed

phenotypes,

differential

regulation

of

key

developmental genes, and abnormal behavioral attributes. In view of this, we present
additional evidence of toxicities resulting from THC and CBD developmental exposure as
well as multigenerational consequences of an F0 only exposure.
Key developmental stages (e.g., toddler through adolescence) are sensitive to
cannabinoid

toxicities

due

to

important

periods

of

neurodevelopment

and

neurotransmitter maturation (Pitsilis et al., 2017). Endogenous cannabinoid ligands, (2arachidonoylglycerol (2-AG) and N-arachidonoylethanolamide (AEA), as well as
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cannabinoid receptors 1 and 2 (CB1 and CB2) are present at varying concentrations and
expression levels, respectively in zebrafish, chick, rodent, and human development (Fride
et al., 2009; Krug and Clark, 2015; Psychoyos et al., 2012). In zebrafish, developmental
CB1 knockdown studies have been conducted to assess its functional characteristics
(Watson et al., 2008). In these studies, CB1 morpholino mutants exhibited a distinct
phenotype of disorganized medial longitudinal fasciculi (MLF) and disturbed axonal
growth (Watson et al., 2008). In chick and rodent studies, cannabinoid receptors, which
are among a class of G-protein coupled receptors (GPCRs) that transduce their signaling
via adenylyl cyclase/cAMP and additional downstream mechanisms, are very active
during early development time periods (Psychoyos et al., 2012). Therefore, exogenous
ligands such as THC or CBD have the ability to alter these endogenous systems leading
to adverse developmental outcomes. Adverse outcomes have previously been measured
in zebrafish following THC exposure, resulting in cognitive impairments such as anxiety,
learning, and memory (Ruhl et al., 2014; Stewart and Kalueff, 2014); however, no
previous study has offered comparative analysis of THC verses CBD.
Similarly a few studies offer insight into the reproductive and multigenerational
consequences of THC exposure, but no previous literature has focused on CBD as a
generational toxicant (Dalterio et al., 1984; Lewis et al., 2012; Thomas, 1975). Previous
research has shown evidence of multigenerational toxicities in rodents following an
adolescent exposure to THC (Watson et al., 2015). The primary findings were a reduction
in pregnancy rates due to parental germline exposure (Szutorisz et al., 2014). The
reduced pregnancy rates were thought to be correlated with reduced male fertility
following THC exposure which is well established (Agirregoitia et al., 2010; Costa et al.,
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2015; Lewis et al., 2012; Nahas et al., 2002). The causality for reduced male fertility has
been less studied; however, CB1 and CB2 are both expressed in human sperm cells and
are implicated in the regulation of sperm motility (Agirregoitia et al., 2010). These
multigenerational, loss of reproductive ability effects are most likely attributed to
epigenetic factors that contribute to altered gene expression phenomena in subsequent
generations (Watson et al., 2015).
Herein, we studied the effects of a F0 generation developmental exposure to THC
or CBD and how that exposure affected both F0 development and their subsequent
offspring (F1; second generation) in the context of biomarker gene expression, behavior,
and reproductive success. This project is novel due to the lack of empirical data
comparing the toxicities of the two most exploited phytocannabinoids, THC and CBD. In
addition, evidence of CBD’s therapeutic potential (Devinsky et al., 2017) in children
diagnosed with drug-resistant forms of epilepsy will inherently increase human exposure
during critical developmental stages.

3.3 Methods and Materials
3.3.1 Zebrafish Care and Exposure
Tg(fli1:egfp) zebrafish were obtained through the Zebrafish International Resource
Center (ZFIN, Eugene, Oregon). In brief, adult zebrafish were spawned overnight in
breeding tanks containing water from an Aquatic Habitats Zebrafish Flow-through System
(Aquatic Habitats, Apopka, Florida) within the following parameters: pH 7.5-8.0, dissolved
oxygen 7.2-7.8 mg/L, conductivity 730-770 μS, temperature 27°-29°C. The next morning,
newly fertilized eggs were randomly sorted into scintillation vials, n = 5 vials per exposure
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group; 10-30 fish per vial depending on exposure time period (14 hpf n≈30, 24 hpf n≈30,
48 hpf n≈25, 72 hpf n≈20, 96 hpf n≈15), containing embryo water with a salinity of 60 ppm
Instant Ocean (Instant Ocean, Cincinnati, Ohio) at pH 7.4-7.7. Beginning at ~2 hpf,
embryos were exposed to concentrations below the LOAEL, as previously described in
(Carty et al., 2017), 0.024, 0.12, 0.6 mg/L (0.08, 0.4, 2 μM) THC, 0.006, 0.03, 0.15 mg/L
(0.02, 0.1, 0.5 μM) CBD, or 0.05% DMSO control water at a 0.6:1 (mLs water:fish) ratio
in static conditions without a water changes. Culture and exposure protocols were
previously IACUC approved. The NIDA Drug Supply Program supplied all THC and CBD
used throughout the developmental exposures.

3.3.2 RT-qPCR
All concentrations (0.024, 0.12, 0.6 mg/L (0.08, 0.4, 2 μM) THC, and 0.006, 0.03,
0.15 mg/L (0.02, 0.1, 0.5 μM) CBD, or 0.05% DMSO) were assessed in the F0 generation,
while only 0.05% DMSO control and high concentrations (0.6 mg/L THC and 0.15 mg/L
CBD) were assessed in F1s. Zebrafish (F0 and F1) were collected and pooled at 14, 24,
48, 72, or 96 hpf (n = 5 vials; 15-30 fish per vial) and placed in RNAlater (Invitrogen) and
then stored at -80°C. Whole embryo/larval tissue was homogenized in TRIzol (Invitrogen
#A33251) and RNA was extracted using RNeasy mini-kit (Qiagen #74104) and RNaseFree DNase set (Qiagen #79254) following manufacturer’s recommended protocol. RNA
was quantified and evaluated for purity on a NanoDrop 2000 followed by reverse
transcription to 10 ng/μL cDNA (Invitrogen kit #4304134). RT-qPCR was performed using
an Applied Biosystems 7200 real-time cycler with SYBR Green detection chemistry
(Applied Biosystems #4309155). Parameters for RT-qPCR were as follows: 95°C for 10
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min, then 40 cycles of 95°C for 15 sec and 60°C for 1 min, followed by 95°C for 15 sec60°C for 1 min-95°C for 15 sec dissociation curve. Primers were optimized previously
(Fang et al., 2013a) and detailed in Table 3.1. Samples were screened using duplicate
analytical standards followed by 2-ΔΔCT method evaluation (Livak and Schmittgen, 2001).
Statistical significance was calculated using one-way analysis of variance (ANOVA) on
the ΔCT followed by Tukey’s post-hoc test (p ≤ 0.05); however, if significance was not
obtained using ANOVA, the student’s t-test (p ≤ 0.05) was subsequently used to measure
significance against control. Error was identified as standard error of the mean (SEM).
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Table 3.1 RT-qPCR Primers
Gene Accession
Primer sequence
F: 5'-CAC CGA TAC ACT GCA AGC TGA A-3'
c-fos BC065466
R: 5'-CAG GTT GGC GAT GTC GTT CT-3'
F: 5'-AAT GCC CAG CTT GCC TAA TG-3'
dazl BC076423
R: 5'-CAC GCG GCC GAA ACC-3'
F: 5’-GAC TCG AAG GAC GTT GAC CTG TA-3’
bdnf BC058301
R: 5’-CGG CTC CAA AGG CAC TTG-3’
F: 5'-TGG TTA ATT CCG ATA ACG AACGA-3'
18s
FJ915075
R: 5'-CGC CAC TTG TCC CTC TAA GAA-3'

r2

Efficiency %

0.997

106.2

0.974

84.06

0.977

97.95

0.999

75.61

3.3.3 Larvae Behavior
F0 generation zebrafish exposed to CBD, THC, or control (n = 2 vials; ~24 fish per
vial) for 96 hpf and unexposed F1 generation zebrafish (96 hpf; n = 36-48) were
transferred to a 96-well plate (one fish per well) followed by a 5-minute acclimation period
in full light. Larvae exhibiting a lack of touch response or deleterious morphology were
excluded from the behavioral assessment. Larval zebrafish were assessed in a ZebraBox
utilizing ZebraLab 3.3 software (ViewPoint, Montreal, Canada). Neurotoxic behavior was
observed via a 30 min period of light:dark cycling (0-10 min, 100% light; 10-20 min, dark,
0% light; and 20-30 min, 100% light) (Kirla et al., 2016). Zebrafish locomotor activity with
a velocity ≥ 5 mm/sec was collected continuously throughout the 30-minute period and
averaged every two minutes for statistical analysis. (n=2 (F0); n = 36-48 (F1)) using twoway ANOVA with repeated measure followed by Bonferroni post-tests (p ≤ 0.05).

3.3.4 Reproductive Assessment
At 6 months of age, mating pairs (2 male:2 female) of each F0 exposure group
were placed into static breeding tanks (n = 3-7 breeding tanks per concentration) with 750
mL system water from our primary zebrafish culture unit (Aquatic Biosystems) and placed
in a temperature controlled room. Water changes were conducted twice a week and
during spawning events. Mating pairs were allowed a one-week acclimation period for
which one spawning event took place. Week two consisted of three consecutive spawning
days to ensure participation from each male and female. Following each egg collection,
debris and water were removed and replaced with clean embryo medium (60 ppm Instant
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Ocean; pH 7.5-7.8). Collected eggs were subsequently counted and screened for
fertilization, mortality, and hatching every 24 hours until 96 hpf.

3.3.5 GC-MS Water Analysis
Exposure concentrations of THC and CBD stock solutions were confirmed in water
at 0 hpf and 96 hpf, as previously described (Carty et al., 2017; Kudo et al., 1995). In
brief, we prepared stock exposure water of 1.25 mg/L THC and 0.3 mg/L CBD (0.05%
DMSO) and diluted to our exposure concentrations. Concentrations in stock water were
verified by removing 2 mLs and adding THC-d3 (Sigma Aldrich) with a final concentration
of 10 mg/L and 1 mL of 2 M NaOH followed by a solvent:water extraction into hexane:ethyl
acetate (H:E) (9:1, v/v). H:E was then evaporated and reconstituted/derivatized in N,OBis(trismethylsilyl)trifluoroacetamide with 1% trimethylchlorosilane (Thermo Scientific) for
1 hour at 90°C. Samples were then re-suspended isooctance and analyzed on GC-MS
(Agilent Technologies 6890N; Mass Spectrometer 5973).

3.4 Results
3.4.1 F0 and F1 Gene Expression
Zebrafish were collected at 14, 24, 48, 72, and 96 hpf and analyzed for differential
gene expression of biomarkers for neurodevelopment (c-fos and brain-neurotrophic
factor, bdnf) as well as germline fitness (deleted-in-azoospermia-like, dazl). Stock
exposure water concentrations were verified via GC-MS as follows: 1.25 mg/L THC
(nominal)  1.13 ± 0.16 mg/L THC and 0.3 mg/L CBD (nominal)  0.08 ± 0.02 mg/L
CBD. Time point analysis of the F0 generation revealed c-fos to be differentially down73

regulated, especially later in development (48, 72, and 96 hpf) and at high concentrations
of THC (0.6 mg/L THC) (Figure 3.1). bdnf also displayed aberrant up-regulated patterns
of expression at multiple time points (14, 48, and 96 hpf) mostly at 0.6 mg/L THC. While
dazl also shared differential down-regulation at 96 hpf (0.12 mg/L THC) with c-fos, 14
(0.024 mg/L THC) and 72 hpf (0.6 mg/L THC) were up-regulated compared to control
(Figure 3.1).
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Figure 3.1 THC time point gene expression (F0). Developmental stage specific differential
expression of c-fos (A-C), bdnf (D-G), and dazl (H-K) following exposure to THC or
DMSO. Line graphs depict the developmental expression patterns normalized to 14 hpf.
Bar charts represent time points that were statistically significant throughout development
normalized to control. Exposure groups were normalized to 18s and analyzed using the
2-ΔΔCT method (p ≤ 0.05) measured first by ANOVA and Tukey’s post-hoc test (#) or
student’s t-test (*) (n = 5). c-fos was differentially down-regulated later in development
(48, 72, and 96 hpf) at 0.6 mg/L THC. bdnf and dazl were primarily up-regulated early
and late in development including potential concentrations dependence at 48 hpf (bdnf;
0.6 mg/L THC) and 72 hpf (dazl; 0.6 mg/L THC). Bars represent ± SEM.
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CBD developmental F0 exposure lead to fewer significant changes in gene
expression. c-fos expression at 96 hpf (0.15 mg/L CBD) was significantly higher than
control; however, at 96 hpf c-fos expression was significantly down-regulated following
exposure at the lower 0.006 and 0.03 mg/L CBD concentrations (Figure 3.2). bdnf was
consistently up-regulated during development at 24 and 72 hpf, but only at the highest
concentrations of CBD (0.15 mg/L; Figure 3.2). While dazl was differentially expressed
throughout development following THC exposure, CBD was only affective in changing
expression characteristics early in development (14 hpf) at 0.15 mg/L (Figure 3.2).
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Figure 3.2 CBD time point gene expression (F0). Developmental stage specific differential
expression of c-fos (A,B), bdnf (C-E), and dazl (F,G) following exposure to CBD or DMSO.
Line graphs depict the developmental expression patterns normalized to 14 hpf. Bar
charts represent time points that were statistically significant throughout development
normalized to control. Exposure groups were normalized to a reference gene (18s) and
analyzed using the 2-ΔΔCT method with significance (p ≤ 0.05) measured first by ANOVA
and Tukey’s post-hoc test (#) or student’s t-test (*) (n = 5). c-fos was significantly upregulated at 24 hpf (0.15 mg/L CBD), but down-regulated at 72 hpf (0.006 and 0.03 mg/L
CBD). At 24 and 72 hpf, bdnf was differentially upregulated at 0.15 mg/L CBD, while dazl
expression was only significantly affected at 14 hpf (0.15 mg/L CBD). Bars represent ±
SEM.
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Fewer adverse changes in gene expression were observed in the F1 generation.
No significant changes in c-fos or bdnf expression in the F1s were detected. Only dazl
expression was significantly up-regulated in the F1 generation at 48 and 96 hpf following
developmental exposure to F0 parents at 0.15 mg/L CBD (Figure 3.3).
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Figure 3.3 THC and CBD developmental gene expression (F1). F1 developmental stage
specific differential expression of c-fos, bdnf, and dazl following exposure to THC, CBD,
or DMSO via RT-qPCR. Exposure groups were normalized to a reference gene (18s) and
analyzed using the 2-ΔΔCT method with significance (p ≤ 0.05) measured by student’s ttest (p ≤ 0.05) (n = 5). For reference, line graphs depict the developmental expression
patterns normalized to 14 hpf, while the bar charts represent time points that were
statistically significant. THC (0.6 mg/L) did not provide any multigenerational differential
expression (F1) following a development exposure to F0 parents. However, offspring of
parents developmentally exposed to 0.15 mg/L CBD differentially expressed dazl at 48
and 96 hpf. Bars represent ± SEM.
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3.4.2 F0 and F1 Locomotor activity
Locomotor activity was conducted at 96 hpf and limited to larvae with normal
morphologic features. In F0 larvae, statistically significant hypolocomotor activity was only
observed in larvae exposed to the lowest concentration of THC (0.6 mg/L), (Figure 3.4).
No additional statistically significant locomotor activity was detected in F0s compared to
control. F1 larvae presented more significant behavioral phenotypes. F1 larvae from
parents exposed to the lowest concentration of THC (0.024 mg/L) displayed a reduction
in locomotor activity at 12-20 minutes of darkness, mirroring their parents’ hypolocomoter
phenotype (Figure 3.4). However, we did not observe a concentration dependence in
locomotor activity in THC F1s exposed offspring. Offspring of parents exposed to 0.12
mg/L THC exhibited increased locomotor activity, while the highest concentration (0.6
mg/L THC) proved to be unchanged compared to control (Figure 3.4). F1 larvae from 0.03
mg/L CBD exposed parents displayed a reduction in locomotor activity while their parents,
at the larval stage, were unaffected.
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Figure 3.4 THC and CBD larval zebrafish behavior in F0 (A,B) and F1(C,D). F0 and F1
larval zebrafish behavior were assessed at 96 hpf for locomotor activity in a ViewPoint
ZebraBox for a total of 30 minutes (0 – 10 min, light: 10 – 20 min, dark (grey box): 20 –
30 min, light) as described in (Carty et al., 2017). Locomotor durations greater than a
velocity of 5 mm/sec were averaged per 2 minute time frame and analyzed for statistical
significance using two-way ANOVA with repeated measures followed by Bonferroni posthoc test (n = 2 (F0), n = 36-48 (F1), p ≤ 0.05). Concentrations along with (n) are provided
in the graphs above. Bars represent ± SEM.
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3.4.3 F0 Reproductive Success and F1 Survival
Following three consecutive days of egg collection from 6-month old F0
developmentally exposed to sub-LOAEL concentrations of either THC or CBD, total
offspring, survival, fertilization, and hatching rate were examined (Table 3.2). When
comparing total eggs, we observed a trend toward reduced fecundity in F0s exposed to
CBD (0.024 mg/L) and THC (0.024 and 0.12 mg/L) (Table 3.2). It should be noted, two
control tanks did not perform well due to uncharacteristically low fecundity and abnormally
high mortality rates; therefore, we omitted these tanks from our statistical analysis.
Survival and fertilization percentages were not affected in the F1 generation. While we
have previously observed delayed hatching rates in zebrafish larvae exposed to high
concentrations of CBD (Carty et al., 2017), at sub-LOAEL concentrations we did not find
any significant change at 48 or 72 hpf (Table 3.2).
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Table 3.2 F0 fecundity and F1 survival
Nominal Water
Total Eggs/
Compound
Concentration mg/L
Average per
at 0 hpf (tanks)
tank
Control
0.05% DMSO (7)
1050/150
THC
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CBD

% Survival

% Fertilized

% Hatched
48 hpf

% Hatched
72 hpf

74.0 ± 7.2

98.5 ± 1.0

11.7 ± 6.2

79.3 ± 11.4

0.024 (3)

192/64a

89.8 ± 4.8

100.0 ± 0.0

16.8 ± 14.2

95.7 ± 2.3

0.12 (3)

183/61a

60.4 ± 31.8

99.2 ± 0.8

25.0 ± 14.1

99.2 ± 0.8

0.6 (6)

554/111

97.7 ± 1.3

93.5 ± 5.4

16.6 ± 4.7

94.7 ± 2.6

0.006 (6)

1152/192

86.6 ± 5.2

95. 1 ± 2.2

23.7 ± 4.2

83.2 ± 8.2

0.03 (6)

683/114

87.3 ± 5.2

98.6 ± 0.4

14.4 ± 2.7

96.0 ± 1.5

0.15 (4)

253/63a

60.4 ± 9.2

90.7 ± 8.1

11.2 ± 4.0

86.6 ± 12.2

± SEM
a One-way ANOVA; Tukey’s (p < 0.05)

3.5 Discussion
Cannabinoid exposure is increasing among young children and adolescents due
to therapeutic advancements for the treatment of drug-resistant epilepsy (Devinsky et al.,
2017); therefore, the goal of this study was to assess the multigenerational risk of early
life exposure to either THC or CBD. An important finding from this research is the potential
carry-over of differentially expressed genes that may lead to reduced reproductive
success.
Belonging to the Daz gene family, dazl is involved in male infertility and primordial
germ cell (PGC) formation. PGCs emerge early in development from maternally inherited
germplasm and are essential for spermatocyte and oocyte success leading to
multigenerational lineage (Seervai and Wessel, 2013). Many factors, including dazl, are
involved in germplasm organization which is imperative for the formation of viable PGC
clusters and PGC specificity (Campbell et al., 2015; Hashimoto et al., 2004). Homologues
of dazl, which derives its name from being deleted-in-azoospermia phenotypes, have
been reported across many invertebrate and vertebrate species including Drosophila, C.
elegans, Xenopus, medaka, mice, humans, and zebrafish (Anderson et al., 2007; Li et
al., 2016; Seboun et al., 1997; Takeda et al., 2009). Maternally inherited dazl has been
observed in newly fertilized zebrafish embryos as early as the 4-cell stage (1 hpf) through
the sphere stage (4 hpf) and located distally in cleavage planes (Hashimoto et al., 2004);
therefore, evidence suggests dazl is involved in both zebrafish embryogenesis and PGC
development (Hashimoto et al., 2004). In this study, we use dazl expression as a
correlative marker for germline fitness leading to compromised reproductive success in
subsequent generations (Li et al., 2016).
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Previously, we have studied dazl and how its expression is sensitive to xenobiotic
exposure

via

hypermethylation

patterns.

Specifically,

parental

exposure

to

benzo[a]pyrene (BaP) caused hypermethylation of the dazl promoter and decreased dazl
gene expression leading to a reduction in germline formation and F1 offspring (Corrales
et al., 2014). Herein, we assessed dazl expression as early as 14 hpf due to PGCs
completing their migration to gonadal tissue at roughly the 15-somite stage (16.5 hpf)
(Dosch, 2015). Following CBD exposure in F0 larvae, dazl was differentially expressed in
both F0 and F1 generations. In the F0s, THC and CBD differentially expressed dazl during
the segmentation stage (14 hpf) of developmental which can effect germline development
and PGC maturation. We also observed a significant decrease in offspring coupled in
zebrafish with down-regulated dazl. In the F1 generation, dazl was differentially
expressed, which may be less impactful on subsequent generations; however, future
generations will also be assessed to determine potential rescued reproductive
phenotypes.
The potential adverse effects of dazl expression are not limited to zebrafish. In
mice, dazl mutations lead to a loss of oocyte formation in females and a complete loss of
germ cells regardless of sex (Ruggiu et al., 1997). DazlaTm1hgu/+ and DazlaTm1hgu/
DazlaTm1hgu male mice produce very little or no sperm, respectively, while in homozygous
females lack ova and follicles. In addition, ovary tissue was markedly decreased
compared to wild-type and histology of testicular tissue showed a significant interruption
in germ cell formation during spermatogenesis (Ruggiu et al., 1997). In humans, dazl
expression in ovary can be measured as early as gestational day sixty one and increases
exponentially through gestational week nineteen (Anderson et al., 2007). While
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expression of dazl in human fetal testis is lower compared to ovary tissue, dazl is
expressed consistently from first and second trimesters. Also, germ cell size in fetal tissue
directly correlates with cells expressing the DAZL protein rather than adjacent cells only
expressing another germ cell protein, VASA (Anderson et al., 2007). dazl has proven to
be a very important developmental and reproductive biomarker across many species and
the effect of cannabinoids on dazl expression has not previously been shown.
In order to assess neurodevelopment and potential neuronal activity in exposed
larvae, we measured c-fos and bdnf at multiple developmental time points. Our
observations concluded that unexposed F1 generation larvae expressed c-fos and bdnf
similar to control and were not sensitive to parental exposure to THC or CBD. However,
F0 larvae exposed to THC or CBD were sensitive to cannabinoid exposure resulting in
differentially expressed c-fos and bdnf throughout development. The rationale for using
c-fos in this study to represent neuronal activity is well established (Baraban et al., 2005;
Buenafe et al., 2013; Ellis et al., 2012; Kalueff et al., 2014; Rahn et al., 2015). c-fos
expression has also been directly correlated with seizure generation as well as anxiety
behavior (Baraban et al., 2005; Jesuthasan, 2012).
Medicinal cannabis, as it relates to c-fos expression, may be important in future
studies to determine the therapeutic potential of not only reducing behavioral phenotypes
of epilepsy, but also molecular mechanisms leading to seizure propagation. For example,
CBD can reduce protein levels of c-fos and reduce catalepsy phenotypes due to
haloperidol exposure in male Swiss mice (Sonego et al., 2016). Interestingly, the
attenuation of catalepsy behavior is likely 5-HT1A mediated as opposed to typical GPCR
signaling (Sonego et al., 2016). While CBD signal transduction pathways are still under
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investigation, c-fos is a likely candidate for dysregulation following CBD exposure both
seen in our present study and in current literature.
bdnf is ubiquitously expressed throughout human, mammalian, and zebrafish
brains and is critical for CNS function and development (Cacialli et al., 2016; Cunha et
al., 2009; Murer et al., 1999). In mice, bdnf mRNA transcripts have been observed in
newborns through adulthood in the brainstem, cerebral cortex, hypothalamus, and
hippocampus (Hofer et al., 1990). Utilizing immunoreactivity techniques, previous studies
found bdnf expression in normal human brain tissue spread throughout the CNS in cell
bodies of neurons, synaptic boutons, axons, and dendrites (Murer et al., 1999).
Interestingly, human brains of Alzheimer’s disease lack bdnf which directly implicates its
expression with neurodegeneration and cognitive impairment (Peng et al., 2005). While
studies have shown that either a decrease or an increase in bdnf poses a threat for
potential onset of adult disease, a consensus has been met that bdnf is involved in the
process of neuronal impairment, survival, and function (Angelucci et al., 2010).
The primary pathway for BDNF protein signal transduction is through the TrkB
pathway, and they together affect numerous functions including neuronal plasticity,
neuronal survival, learning and memory and as previously mentioned, neurodegenerative
diseases (Bekinschtein et al., 2008; Cacialli et al., 2016; Cunha et al., 2009). In zebrafish,
maternally inherited bdnf is observed through 24 hpf followed by steady endogenous
increase in expression past eight days post fertilization (dpf) (De Felice et al., 2014). We
observed significant up-regulation of bdnf at very early stages of development (14 hpf)
through stages post-embryogenesis (96 hpf). In transgenic mice, BDNF overexpression
has been directly correlated with learning and memory impairment (Cunha et al., 2009).
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Therefore, it is imperative to uncover the possible ramifications of increased bdnf
expression in developing zebrafish. While the F1 generation of THC and CBD exposed
zebrafish did not carry-over a differential expression of bdnf, we have yet to analyze the
adverse effects of larval bdnf expression on adult zebrafish behavior and cognitive
abilities.
Several recent studies outline the therapeutic and potential adverse effects of
cannabinoids and their influence on bdnf expression (Butovsky et al., 2005; Campos et
al., 2015; D’Souza et al., 2009; ElBatsh et al., 2012; Fishbein et al., 2012; Mori et al.,
2017; Winsauer et al., 2015). Consistent with our results, moderate (1.5 mg/kg) and low
(0.002 mg/kg) doses of THC upregulate BDNF expression in various regions of brain
tissue in mice (Butovsky et al., 2005; Fishbein et al., 2012). Additionally, low-doses of
THC can cause minor cognitive impairment, but may potentially be protecting against
severe damage following convulsant exposure such as PTZ (Fishbein et al., 2012).
Regulation of cannabinoid signaling via CB1 can also be modulated by BDNF, which
presents broad implications in cannabinoid mediated toxicities relevant to the EDC (De
Chiara et al., 2010). CBD has also been investigated for potential protective roles in
cognitive impairment as it relates to BDNF expression (Campos et al., 2015; Mori et al.,
2017). Specifically, cerebral malaria (CM) mice, co-treated with artesunate and CBD
experience reduced cognitive deficits versus to artesunate treatment alone (Campos et
al., 2015). More research is needed to identify the exact mechanisms for the detrimental
versus beneficial roles of THC and CBD.
Another major goal of this study was to uncover potential behavior abnormalities
in larval zebrafish following a sub-LOAEL exposure to THC or CBD. We also wanted to
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study the likelihood of F0 behavioral phenotypes carrying-over to the F1 larvae that lacked
direct cannabinoid exposure. In our previous study, THC and CBD caused a
concentration-depend reduction in locomotor behavior in 96 hpf zebrafish leading to
significant hypolocomotor activity at 1.25 mg/L THC and 0.3 mg/L CBD (Carty et al.,
2017). In the current study, we also observed significant hypolocomoter activity, but at
very low concentrations of THC in the F0 generation. Additionally, the F1 generation also
possessed a hypolocomotor phenotype at reduced concentrations of both THC and CBD
compared to control. We are uncertain why THC and CBD affect locomotor activity in a
concentration dependent manner; however, previous work in this area has also reported
an inverted U-shaped locomotor concentration-response to CBD with regard to
anxiogenic behavior (Nazario et al., 2015a). Another interesting aspect of these data is in
c-fos expression. As mentioned previously, c-fos expression has been directly correlated
with seizure-like attributes and our observations follow this trend. c-fos expression in F0s
was down-regulated at 96 hpf in 0.6 mg/L THC and 0.006, 0.03 mg/L CBD exposed
larvae; contrastingly, we did not observe adverse phenotypical behavior in these groups.
F1 generation larvae, at 96 hpf, somewhat mirrored the F0 hypolocomotor phenotypes,
but more research is needed to properly establish an explanation for these results.
Significant observations were made in both molecular markers and reproductive
success; however, there are some limitations to consider. While we verified our stock
exposure concentrations at time 0 hr, some of our measured concentrations at 96 hr were
below the limits of detection for our GC-MS. It was the goal of this study to expose
zebrafish at concentrations in which minimal dysmorphologies were present; however, it
is plausible that higher concentrations could potentially result in increased gene
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expression, reproduction, and behavioral abnormalities. Future studies are necessary to
further elucidate the impact of increased cannabinoid concentrations on development of
F0s and subsequent generations.

3.6 Conclusion
Herein, we established for the first time, a multigenerational zebrafish model for
investigating the potential developmental toxicities following THC or CBD exposure. This
study is relevant due to the increased therapeutic treatment opportunities of cannabinoids
in young children for the treatment of devastating forms of epilepsy. Due to previously
conducted research, our initial hypothesis was that THC would be more multigenerational
and neurologically toxic compared to CBD. While we did observe reproductive
deficiencies and molecular clues for neurotoxicity following THC exposure, we also
observed similar results following CBD exposure. These results indicate a clear need for
additional cannabis-based studies in order to better understand the mechanistic
properties of cannabinoids and to realize the potential risks of its therapeutic application.
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CHAPTER 4 CONCLUSION AND FUTURE DIRECTIONS
Cannabis sativa has been used for several millennia as a homeopathic remedy of
common ailments such as pain, sleep, and hunger. Recently, the chemical elucidation of
cannabis extracts has revealed THC and CBD as the primary active compounds
containing pharmaceutical promise. As mentioned in historical data and through our own
observations, THC is a well-documented developmental, reproductive, and behavioral
toxicant. We used THC as a positive control to measure against the potential toxicities of
CBD, for which less is known. Following a rigorous exposure paradigm to elucidate
phenotypical cannabinoid toxicities, we provide evidence that CBD poses similar risks to
development, reproduction, and behavior as THC. To our knowledge, this is the first study
to

systematically

compare

the

harmful

effects

of

the

two

most

prevalent

phytocannabinoids. In addition, this is the first time our lab has scrutinized behavioral
phenotypes in larval and eventually adult zebrafish as a toxicological endpoint.
In our initial cannabinoid exposure, we exposed Tg(fli1:egfp) zebrafish (~6 hpf) to
0.3, 0.6, 1.25, 2.5, and 5 mg/L (1, 2, 4, 8, 18 μM) THC, 0.07, 0.1, 0.3, 0.6, and 1.25 mg/L
(0.25, 0.5, 1, 2, 4 μM) CBD, or 0.05% DMSO in glass scintillation vials (n = 3 vials per
concentration; 10 fish per vial). Concentrations were selected to be slightly above the
previously published THC LC50 (3.37 mg/L (Noyes et al., 2015)) and extend into relevant
therapeutic concentrations. Zebrafish were then assessed for adverse morphological
phenotypes and behavioral abnormalities, followed by RT-qPCR analysis of important
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developmental biomarkers (Figure 2.1-2.2). While, the previously published THC LC50
was confirmed by our exposure, we did not expect the CBD LC50 to be upwards of seven
times lower. This insinuates that CBD is far more potent than its cannabis counterpart,
THC. In order to test potency, we analytically derived bioconcentration factors from both
THC and CBD and found CBD to be more bioconcentrated than THC. More research is
required to pinpoint additional analytical endpoints such as steady state, entry points,
metabolism, and compound degradation; however, our observations hint that CBD is
simply more bioavailable not necessarily more potent than THC.
In our initial trials, THC and CBD exposures also revealed similar adverse
morphological phenotypes, consistent with a toxic initiating event early in zebrafish
development. Two morphological observations were made characterizing differences
between THC and CBD exposure:


CBD caused dysmorphology at concentrations lower than that of THC, and



at concentrations ≥ 0.6 mg/L CBD, we observed a non-hatched phenotype.
While the analytical chemistry approach answered questions concerning the

higher potency of CBD, we did not investigate the non-hatched or delayed-hatched
phenotypes. Future analysis of CBD’s potential effect on zebrafish hatching enzymes
(Sano et al., 2008) or the likelihood of CBD concentrating on the surface of the chorion
increasing rigidity resulting in reduced shedding could be further investigated.
Molecular endpoints would inform mechanism of action following a developmental
exposure to THC and CBD. From our gene-list that included markers for both neuronal
development and morphogenesis, only c-fos was differentially regulated in a
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concentration-dependent manner. A gene with potentially the most significant
multigenerational implications, dazl, was also deregulated following THC (F0) and CBD
(F1) exposure. Gaps exist in our assessment of differentially expressed genes caused by
THC or CBD exposure; therefore, we are currently embarking on transcriptomic analysis
via RNA-seq of developmentally exposed zebrafish.
Following our initial exposure, we set out to study two additional aspects of
zebrafish development following cannabinoid exposure:
1. Are genes that are critical for neuronal growth and reproductive fitness differentially
regulated at critical stages of development, and
2. is there carry-over of differentially expressed genes to subsequent generations.
In order to answer these questions, we reduced the exposure concentrations which
allowed survival through adulthood. Zebrafish embryos were collected and exposed in a
similar fashion to the initial exposure at concentrations: 0.024, 0.12, and 0.6 mg/L (0.08,
0.4, 2 μM) THC, 0.006, 0.03, and 0.15 mg/L (0.02, 0.1, 0.5 μM) CBD, or 0.05% DMSO (n
= 5; 10 – 30 fish per vial depending on time point). In addition to lower exposure
concentrations, we also assessed gene expression at several time points (14, 24, 48, 72,
and 96 hpf) throughout development of both F0 and F1 generations. THC was more
effective than CBD at deregulating c-fos, bdnf, and dazl throughout development, but
CBD, not THC, caused differential expression (dazl) in the F1 generation. CBD also
decreased offspring in exposed F0s. Correlating dazl expression across generations to
fecundity, especially in F2 generation, is a future aim of this project.
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One major accomplishment of this project was establishing, for the first time in our
lab, a behavioral endpoint for neurotoxicity. Through transitional light:dark locomotor
activity, we were able to characterize a toxicity phenotype of THC and CBD. Low and high
concentrations resulted in reduced locomotor activity, while mid-ranged concentrations
culminated in increased locomotor activity. Unfortunately, a technical mistake was made
in the experimental design leading to reduced samples sizes while conducting statistical
significance. Even though individual larvae were placed in each well of a 96-well plate
and scrutinized separately, the original exposure vessels contained pooled larvae;
therefore, we lost statistical power due to averaging locomotor data per exposure vessels.
Future behavioral exposures should be exclusively conducted in well-plates with
individual larvae in each well.
A future goal is to assess F0 and F1 adult behavior. After 96 hr exposures to
cannabinoids, a subset of larvae (minimally 100 per treatment per concentration) will be
raised in clean conditions to adults (12-16 months). As adults, n = 16 will be subjected to
a T-maze spatial learning test and a 6 min open-field test as described in (Saili et al.,
2012), respectively using Noldus equipment and Ethovision XT tracking software. In the
T-maze one arm will have artificial grass and marbles representing a favorable habitat.
Novelty and social isolation stress will be reduced over 3 days of habituation (1 hr; 2x/day)
followed by 2 training trials (1/ day). On days 5 and 6, in two trials (3 hrs apart), we will
track how long it takes each fish to select and remain in the “favored” reservoir for 20 sec
(n = 16 with 4 trials per fish). If there is a persistent adverse effect on learning, the time
to reach the favored reservoir will not be reduced relative to the earlier test and will be
longer than in controls. In the open field test, fish will be placed in the center of a 21 cm

94

diameter cylinder filled with water to 12 cm. Their movement will be tracked for 6 min to
calculate time spent per zone, distance travelled and number of visits to central and
peripheral zones to characterize thigmotaxis (peripheral swimming). Increased anxiety
will be consistent with erratic movement and thigmotaxis.
Additional future goals include molecular techniques such as whole-mount in situ
hybridization to identify altered gene expression of cannabinoid receptors and
developmental genes in specific tissue, test sex-specific effects on reproduction, and to
potentially even measure gamete viability and quantity. Through these future aims, we
hope to better understand the mechanisms of cannabinoid toxicity and build upon the
challenges of generating an adverse outcome pathway for THC and CBD-mediated
developmental effects.
Some pitfalls that may have limited the results of this project include the medium
in which we exposed developing zebrafish, the zebrafish itself, and larval behavior. Both
THC and CBD are highly lipophilic compounds only soluble at very low concentrations in
water. We anticipated this shortcoming; therefore, we verified all exposure concentrations
in exposure water and exposed zebrafish tissue. We also realize the zebrafish has its
own set of limitations. While the endocannabinoid system is well characterized in
mammals, less research has been conducted to elucidate endocannabinoid function and
signaling in zebrafish. However, endocannabinoid receptor expression patterns in
zebrafish are known at a high enough degree to allow for confidence in this area. Lastly,
zebrafish larval behavior relating to a toxic event during development is still under scrutiny
and more work is necessary to define behavioral phenotypes during early developmental
periods.
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The original null hypothesis (H0) that THC and CBD would not alter gene
expression that support phenotypic/behavioral defects or compromise adult reproduction
were both rejected. These compounds pose a significant risk to zebrafish development
and behavior even at concentrations significantly below the LC50. While most patients
with drug-resistant forms of epilepsy resulting in debilitating seizures are choosing
cannabinoids in desperation, more research is necessary in mechanisms underlying
developmental toxicity to better understand the potential concerns related to their use.
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APPENDIX I Analytical characterization of phytocannabinoids
Extracting THC and CBD from an aqueous environment or larval tissue proved to
be challenging and required extensive optimization. Our method was adopted from (Kudo
et al., 1995) with minor amendments as needed. While final methods are described in
Chapter 2; briefly, THC, CBD, and surrogate standard THC-d3 were extracted from water
or tissue using liquid:liquid extraction techniques using hexane:ethyl acetate (9:1, v/v).
Following the phase transition of THC, CBD, or THC-d3, the cannabinoids were
derivatized using N,O-Bis(trimethylsilyl)trifluoroacetamide with 1% trimethylchlorosaline
(Thermo Scientific), reconstituted in isooctane, and quantified on a GC-MS (Agilent
Technologies 6890N; Mass Spectrometer 5973) with DB-5MS column (Agilent
Technologies). GC-MS parameters were as follows: starting temperature of 100°C (3
min), ramp to 180°C (30°/min), ramp to 300° (10°C/min), 300° (3 min). Helium was the
gas phase at 25 kPa with a flow of 0.5 mL/min (Kudo et al., 1995). Calibration curves
were prepared similar to samples by spiking known concentrations in hexane:ethyl
acetate (9:1) followed by derivatization and resuspension in isooctane. Standards
contained THC, CBD, and THC-d3 at 0.016, 0.08, 0.4, 2, and 10 mg/L. Figure A1.1 depicts
the calibration curve, slope-intercepts and R2 values for all three cannabinoids. GC-MS
chromatograms and structures for THC (Figure A1.2), CBD (Figure A1.3), and THC-d3
(Figure A1.4) as well as a chromatogram of a single sample containing all three
compounds (Figure A1.5) are also shown.
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Figure A1.1 THC, CBD, and THC-d3 Calibration Curves. THC, CBD, and THC-d3 were
spiked into 9:1 (v/v) hexane:ethyl acetate followed by derivatization. Representative R2
values and slope-intercept equations are depicted above. Y-axis (GC-MS abundance),
X-axis (mg/L).
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Figure A1.2 Representative chromatogram generated by derivatized THC (10 mg/L).
Retention time, 8.167 min; quantitative ion, 386 m/z; qualitative ion, 371 m/z.
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Figure A1.3 Representative chromatogram generated by derivatized CBD (10 mg/L).
Retention time, 6.936 min; quantitative ion, 390 m/z; qualitative ion, 458 m/z.

123

Figure A1.4 Representative chromatogram generated by derivatized THC-d3 (10 mg/L;
I.S. concentration). Retention time, 8.142 min; quantitative ion, 389 m/z; qualitative ion,
374 m/z.
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Figure A1.5 Chromatogram of derivatized CBD, THC, and THC-d3 (all at 10 mg/L) in same
sample.
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In order to verify cannabinoid concentrations in water and tissue, as well as to
assess the relative loss of THC and CBD throughout our exposure periods (0, 4, 14, 24,
48, 72, 96 hpf), THC (Figure A1.6) and CBD (Figure A1.7) were analyzed in exposure
water, with and without zebrafish, as well as the amount bioconcentrated in larval tissue.
Concentrations of THC and CBD decreased throughout the 96-hour exposure period in
water in vials both with and without fish. After 96 hours, exposure water including
zebrafish contained less THC and CBD than water samples where zebrafish were not
added. We believe this result is due to tissue uptake; however, more analysis is needed
in order to track the exact fate of cannabinoids in an aqueous medium within glass vials
containing organic matter.
We also assessed the concentrations of bioconcentrated THC and CBD in larval
tissue at 0, 4, 24, 48, 72, and 96 hpf. Concentrations of THC and CBD increased over
time and peaked at 96 hpf (62.9 μg/g THC and 238.4 μg/g CBD) (Figure A1.6 and A1.7).
However, it should be noted that only the highest concentrations (2.5 mg/L THC and 0.3,
0.6, 1.2 mg/L CBD) were within detection limits. In chapter 3, the increased
bioconcentration of CBD or THC which seems to be independent of THC and CBD’s
individual lipophilicity is discussed.
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Figure A1.6 Time point exposure analysis of THC. THC concentrations decreased over
time similarly in water with and without zebrafish present. THC is most likely
bioconcentrating in tissue which is decreasing water availability and in turn decreasing
detectable H2O concentrations while increasing tissue concentrations. THC (2.5 mg/L)
was highly bioconcentrated, while lower concentrations were undetectable.
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Figure A1.7 Time point exposure analysis of CBD. CBD behaved similarly to THC in
dosed water with and without zebrafish present. CBD bioconcentrated in fish exposed to
0.3, 0.6, and 1.2 mg/L CBD, but was undetectable at lower H2O concentrations (0.075
and 0.15 mg/L).
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APPENDIX II F0 biomarker gene expression
During the initial F0 THC and CBD exposures, gene expression of multiple genes
(vasa, sox9a, sox3, sox2, rln, krit1, cnr1, bdnf) was measured and found to be nonsignificantly changed relative to controls. These non-significant results were excluded
from our publication in Toxicological Sciences and Chapter 2. For future reference, this
data is included in Figure A2.1.
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Figure A2.1 Insignificant Chapter 2 THC and CBD gene expression at 96 hpf (F0). RTqPCR results for which no significance was found compared to control (0.05% DMSO)
following a 96 hpf exposure to THC or CBD. Significant differential expression was
observed in vasa expression between 0.3 mg/L THC and 1.25 mg/L THC; however, no
statistical difference was observed compared to control. All data points were analyzed via
one-way ANOVA followed by Tukey’s post-hoc test.
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APPENDIX III F0 and F1 multigenerational gene expression
Time point analysis of c-fos, bdnf, and dazl expression in the F0 and F1 generation
generated comprehensive amounts of PCR data. To make Chapter 3 and subsequent
publications more concise, compiled data and PCR results lacking statistical significance
were omitted. For full disclosure and future reference, all data is included below in Figures
A3.1-A3.4.
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Figure A3.1 Compiled developmental stage specific gene expression from Chapter 2 (F0).
Time and concentration dependent trends of c-fos, bdnf, and dazl expression following
F0 embryonic exposure of THC or CBD measure at 14, 24, 48, 72, and 96 hpf. Results
are normalized to their individual time point controls (n=5, p<0.05)
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Figure A3.2 Non-significant F1 developmental stage specific gene expression from
Chapter 3 (c-fos). c-fos was upregulated during early development (14, 24, and 48 hpf)
in unexposed offspring from parents exposed to CBD, but this data was not statistically
significant using one-way ANOVA and Tukey’s post-test or student’s t-test compared to
control. Normalized to control at each developmental time point. (n=5, p<0.05)
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Figure A3.3 Non-significant F1 developmental stage specific gene expression from
Chapter 3 (bdnf). bdnf expression was not differentially regulated during zebrafish
development in offspring from parents exposed to either THC or CBD using one-way
ANOVA and Tukey’s post-test or student’s t-test. (n=5, p<0.05)
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Figure A3.4 Non-signficant developmental stage specific gene expression from Chapter
3 (dazl). While dazl expression was statistically different at 48 and 96 hpf, dazl expression
was not differentially regulated at 14, 24, or 72 hpf in offspring from parents exposed to
either THC or CBD using one-way ANOVA and Tukey’s post-test or student’s t-test. (n=5,
p<0.05)
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